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1.1. ORAL SOLID DOSAGE FORMS 
1, 2, 3
 
 Oral route is the most widely used route of administration among all the routes 
that have been developed for systemic controlled delivery of drugs. 
This is due to following reasons:  
1. Oral route is most convenient and uncomplicated  
2. Ease of administration and safe  
3. Improved patient compliance  
4. Cost-effective 
 Oral solid forms such as tablets and capsules has been formulated and developed 
nowadays since they are most effective routes of administration of a new drug. 
Pharmaceutical products designed for oral delivery and currently available on the 
prescription and over the counter markets are mostly immediate release type, which is 
designed for immediate release of drug for rapid absorption. 
 
1.1.1. TABLET
2
 
 Tablet is defined as a compressed solid dosage form containing medicaments with 
or without excipients. Pharmaceutical tablets are solid, flat or biconvex dishes, unit 
dosage form, prepared by compressing a drugs or a mixture of drugs, with or without 
diluents. They vary in shape and different greatly in size and weight, depending on 
amount of medicinal substance and the intended mode of administration. It is the most 
popular dosage form and 70% of the total medicines are dispensed in the form of tablet.  
 
Advantages of the tablet dosage form  
 They are unit dosage form and greatest capabilities of all oral dosage form for the 
greatest dose precision and the least content variability. 
 Cost is lower of all oral dosage form. 
 Lighter and compact. 
 Easiest and cheapest to package and strip. 
 Easy to swallowing with least tendency for hang-up. 
 Sustained release product is possible by enteric coating. 
 Objectionable odor and taste can be masked by coating technique. 
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 Suitable for large scale production. 
 Greatest chemical and microbial stability over all oral dosage for. 
 
Disadvantages of tablet dosage form  
 Elderly ill and children could have problem in swallowing the tablets. 
 Some drugs resist compression into dense compacts, owing to amorphous nature, 
low density character.  
 Drugs with poor wetting, slow dissolution properties, may be difficult to 
formulate or manufacture as a tablet that will still provide adequate or full drug 
bioavailability. 
 
1.1.2. Different types of tablets 
A. Tablet ingested orally:  
 Compressed tablet  
 Multiple compressed tablet  
o Compression coated tablet (Press coated tablet) 
o Layered tablet Inlay tablet  
 Repeat action tablet  
 Delayed release tablet  
 Sugar coated tablet 
 Film coated tablet  
 Chewable tablet  
 Targeted tablet 
B. Tablets used in oral cavity:  
 Buccal tablet  
 Sublingual tablet 
 Troches or lozenges 
 Dental cone  
C. Tablets administered by other route:  
 Implantation tablet  
 Vaginal tablet  
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D. Tablets used to prepare solution:  
 Effervescent tablet  
 Hypodermic tablet  
 Tablet triturates  
 
1.2. IMMEDIATE RELEASE DRUG DELIVERY SYSTEM
5, 6
 
DEFINITION
5
  
 Immediate release drug delivery system are based on single or multiple-unit 
reservoir or matrix system, which are designed to provide immediate drug levels in short 
period of time. 
 
1.2.1 DESIRED CRITERIA FOR IMMEDIATE RELEASE DRUG DELIVERY 
SYSTEM  
 Immediate release dosage form should dissolve or disintegrate in the stomach 
within a short period.  
 In the case of liquid dosage form it should be compatible with taste masking.    
 Be portable without fragility concern.   
 Have a pleasing mouth feel.  
 It should not leave minimal or no residue in the mouth after oral administration. 
 Exhibit low sensitivity to environmental condition as humidity and temperature.  
 Be manufactured using conventional processing and packaging equipment at low 
cost.  
Merits of Immediate Release Drug Delivery System  
 Improved compliance/added convenience  
 Improved stability, bioavailability  
 Suitable for controlled/sustained release actives  
 Allows high drug loading.  
 Ability to provide advantages of liquid medication in the form of solid 
preparation.  
 Adaptable and amenable to existing processing and packaging machinery  
 Cost- effective  
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 Improved solubility of the pharmaceutical composition;  
 Decreased disintegration and dissolution times for immediate release oral dosage 
forms; 
1.2.2. Super Disintegrants
6
: A disintegrant is an excipient, which is added to a tablet or 
capsule blend to aid in the breakup of the compacted mass when it is put into a fluid 
environment.  
Advantages:  
 Effective in lower concentrations  
 Less effect on compressibility and flowability  
 More effective intragranularly  
Some super disintegrants are:  
 1.  Sodium Starch Glycolate used in concentration of 2-8 % & optimum is 4%. 
Mechanism of Action: Rapid and extensive swelling with minimal gelling. 
 2.   Microcrystalline cellulose used in concentration of 2- 15% of tablet weight 
 3. Cross-linked Povidone or crospovidone used in concentration of 2-5% 
Mechanism of Action: Water wicking, swelling and possibly some deformation recovery. 
Rapidly disperses and swells in water, but does not gel even after prolonged exposure.  
 4.  Croscarmellose sodium: Effective Concentrations: 1-3% Direct Compression, 
2-4% Wet Granulation. Mechanism of Action: Wicking due to fibrous structure, swelling 
with minimal gelling.  
 
1.3. Press-coated delivery systems
4, 7, 8
      
Press coating technology  
Press-coating, also referred to as double compression coating, compression 
coating, or dry coating, is an old technique first proposed by Noyes in an 1896 patent. An 
industrial application of this technique was introduced during the period 1950–1960 to 
allow the formulation of incompatible drugs. Press coating found increasing application 
during the past two decades; the process does not require solvents, has a relatively short 
manufacturing process, and achieves a greater increase in mass of the core tablet than 
solvent-based methods do. Although it is an old concept, press coating is a novel 
technology for the formulation of new DDS systems.  
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The technique requires a specific tablet press, with compression coating 
capability. The press coating technique offers many advantages, such as protection of 
hygroscopic, light sensitive, oxygen labile, and acid-labile drugs, isolation of 
incompatible drugs from each other, and provides a method for both sustained drug 
release and modification of the drug release profile. 
In general, a press-coated tablet consists of an inner core tablet and an outer 
coating shell. The outer layer surrounds the inner core, and so selection of outer layer 
materials has a significant impact on the performance of the tablet, including the coating's 
mechanical strength, drug release characteristics, and tablet stability. It is also possible to 
produce combination dosage forms, in which two active substances target different areas 
of the gastrointestinal tract.  
Press coating allows the physical separation of incompatible drugs in the core and 
coat within the same dosage form. Direct compression of both the core and the coating 
shell can remove the necessity for a separate coating process. Any type of material with 
adequate compaction properties can be used for the coating shell. More recently, DDSs 
based on press-coated functional layers have been proposed for delayed, pulsatile, and 
programmable release of different drugs in a single tablet. The press- coating technique 
has been used to modify the drug release of many drugs, mask a medication's bitter taste, 
and protect volatile substances. The technique offers several unique features, such as no 
requirement for special coating solvents or coating equipment and short manufacture 
times. Recently, the application of this technology was investigated in the development of 
timed release dosage forms, time clock systems, and delayed-release tablets.  
The press-coated tablet may consist of a fast disintegration or modified release 
core coated by compression with a solid barrier, commonly made of polymeric material, 
a diluent (as a release modifier) and drug (for either rapid or extended release).  
Press-coated tablets may be modified to provide different release patterns, by varying the 
drug distribution and type of polymers used in the core and outer coating shell. The 
resulting modified drug release may be dependent on the time, pH, or microbial control to 
target a specific region in gastrointestinal tract. Thus, press-coating may be classified as a 
chronopharmaceutical technology, in that it provides a solid dosage form for drug 
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delivery in a pulsatile fashion rather than continuously, and at predetermined times and 
sites following oral administration. 
 
1.3.1 Manufacturing process of press coating
8
 
The inner core tablet is formulated, and then compressed under appropriate 
conditions. The tableting machine die is pre-filled with shell-coating materials to form a 
powder bed, the compressed inner core tablet is placed at the center of the bed, and any 
remaining outer coating shell materials added. Finally, the outer coating shell is 
compressed around the inner core tablet.  
1.3.2. Factors Affecting Performance and Drug Release of Press-Coated Delivery 
Systems
7, 8
  
 Press-coated tablets have two layers, an inner core compressed as a small tablet 
and an outer shell. The core tablet may additionally be dry-coated with rate controlling 
materials such as controlled release polymers and fillers   
Inner core tablet  
 The inner core of the press-coated tablet may comprise pure drug crystals, drug-
excipient blends, granules, microspheres and beads. It is also possible to incorporate 
materials into the core tablet to facilitate disintegration, or otherwise modify the drug 
release. 
 Drug solubility 
 Core composition variables 
o Osmotic agent incorporated. 
o Excipients and polymers contained within the core. 
 Amounts of inner core 
 Compression pressure 
 Location of inner core 
Outer coating shell  
To design a press-coated tablet, the outer shell is a key in ensuring that medication will 
reliably reach the predetermined site following oral administration. Press coating 
involves direct compression of both the inner core and the outer coating shell, without 
separate coating processes or the use of coating solutions. The drug form is manufactured 
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by compressing a tablet within a tablet, so that the outer shell becomes a coating layer. 
Various drug release mechanisms become available by incorporating different polymers 
or other materials into the outer shell formulation, or by increasing the layer's thickness. 
An outer shell made of a rupturable, swellable, or erodible coating, or a permeation 
coating using combinations of hydrophilic and hydrophobic polymers, can modulate the 
speed of water penetration into the outer layer to control drug release. The outer coating 
shell of the press-coated tablet may also provide the initial dose of drug.   
 Polymer particle size 
 Formulation variables 
 Compression pressure 
 Amounts of outer shell 
 Double layered outer shell 
 Compressibility and layer-binding 
 
1.3.3. Recent techniques for press coating technology
7
 
 The novel ENCORE™ 
 One-step dry-coated tablet (OSDRC) method 
 Pulse-echo ultrasonic approach and  
 X-ray computed tomography (CT) technique  
 The technique has been applied to solve manufacturing problems with central 
position deviation and absence of a core in the press-coated tablet. 
 
1.4. Floating Drug Delivery System (FDDS) 
12, 13, 14
 
 Floating systems or hydrodynamically controlled systems are low-density systems 
that have sufficient buoyancy to float over the gastric contents and remain buoyant in the 
stomach without affecting the gastric emptying rate for a prolonged period of time .While 
the system is floating on the gastric contents, the drug is released slowly at the desired 
rate from the system. After release of drug, the residual system is emptied from the 
stomach .This results in an increased gastric residence time and a better control of the 
fluctuation in plasma drug concentration.  
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Advantages of FDDS
13
  
 Improved drug absorption, because of   increased gastric residence time and more 
time spent by the dosage form at its absorption site     
 Controlled delivery of drugs.  
 Delivery of drugs for local action in the stomach.   
 Minimizing the mucosal irritation due to drugs, by drug releasing slowly at 
controlled rate.  
 Treatment of gastrointestinal disorders such as gastro-esophageal reflux.  
 Simple and conventional equipment for manufacture.  
 Ease of administration and better patient compliance.  
 Site-specific drug delivery.  
 
Disadvantages of FDDS
14
 
 Floating systems are not feasible for those drugs that have solubility or stability 
problems in gastric fluids. 
 Gastric retention is influenced by many factors such as gastric motility, pH and 
presence of food. These factors are never constant and hence the buoyancy cannot 
be predicted. 
 Drugs that cause irritation and lesion to gastric mucosa are not suitable to be 
formulated as floating drug delivery systems. 
 
1.4.1. Suitable Drug Candidates for FDDS
12
 
 Drugs with narrow absorption window in GIT, e.g., Riboflavin and Levodopa  
 Drugs that primarily absorbed from stomach and upper part of GIT, e.g., Calcium 
supplements, chlordiazepoxide and cinnarazine.  
 Drugs that act locally in the stomach, e.g., Antacids and Misoprostol.  
 Drugs that degrade in the colon, e.g., Ranitidine HCl and Metronidazole.  
 Drugs that disturb normal colonic bacteria, e.g., Amoxicillin Trihydrate. 
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1.5. MODIFIED DRUG RELEASE PREPARATIONS
7, 8
 
During the early 1990s, second-generation modified-release drug preparations 
achieved continuous and constant-rate drug delivery, in which constant or sustained drug 
output minimize drug concentration “peak and valley” levels in the blood, so promoting 
drug efficacy and reducing adverse effects. Modified-release drug preparations are 
expected to provide reduced dosing frequency and improved patient compliance 
compared to conventional release preparations. Second generation modified-release 
dosage forms include slowed-release, delayed-release, prolonged-release, extended-
release, repeated-release, sustained-release, and controlled-release drug preparations. 
Several controlled-release preparations present numerous problems such as resistance and 
drug tolerance, and activation of the physiological system due to long- term constant drug 
concentrations in the blood and tissues. 
Recent studies reveal that the body’s biological rhythm may affect normal 
physiological function,  including gastrointestinal motility, gastric acid secretion, 
gastrointestinal blood flow, renal blood flow, hepatic blood flow, urinary pH, cardiac 
output, drug-protein binding, and liver enzymatic activity, and biological functions such 
as heart rate, blood pressure, body temperature, blood-plasma concentration, intraocular 
pressure, stroke volume and platelet aggregation. Most organ functions vary with the time 
of the day, particularly when there are rhythmic and temporal patterns in the 
manifestation of a given disease state. The symptoms of many diseases, such as bronchial 
asthma, myocardial infarction, angina pectoris, hypertension, and rheumatic disease have 
followed the body’s biological rhythm. Day-night variation in asthmatic dyspnea and 
variations in the incidence of myocardial infarction occur throughout the early morning 
hours. 
Controlled release medications deliver continuous treatment, rather than 
providing relief of symptoms and protection from adverse events solely when necessary, 
the development of a third-generation of advanced drug delivery systems (DDSs) to 
optimize and create new innovative DDS which provide a defined dose, at a chosen rate, 
at a selected time, to a targeted site is now a growing challenge. A chronodelivery 
system, based on biological rhythms, is a state of the art technology for drug delivery; 
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chrono-modulated DDSs not only increase safety and efficacy levels, but also improve 
overall drug performance. 
1.5.1. Chronopharmaceutics 
7, 11
 
It is evident that drug delivery and therapy should be modified to achieve an 
efficient drug level at an optimum time, rather than merely maintaining constant drug 
concentrations.  Thus, the time-controlled function of third-generation DDSs currently 
under development is finding application in new and improved disease therapeutics. 
Biological rhythms may be applied to pharmacotherapy by adopting a dosage form that 
synchronizes drug concentrations to rhythms in disease activity. During the past two 
decades, diseases that follow rhythmic patterns have given rise to the creation of new 
drug delivery dosage forms, called chronopharmaceuticals.  
Chronopharmaceutics includes the fundamentals and research into various aspects of 
chronophysiology, chronopathology, chronogenetics, chronopharmacology, 
chronopharmacokinetics, chronopharmacodynamics, chronotherapeutics, and 
chronotoxicology. Broadly, chronopharmaceutics bring together chronobiology and 
pharmaceutics.  
Chronobiology
11
 is the study of biological rhythms and mechanisms in living 
systems. It assumes that the bioprocesses and functions of all living organisms exhibit 
predictable variability over time.  
Pharmaceutics is one of the most diverse subject areas in all of pharmaceutical 
science and deals with both the scientific and technological aspects of the design and 
manufacture of dosage forms for medicines to assure their safety, effectiveness, quality, 
and reliability. Thus, chronopharmaceutics is defined as a branch of pharmaceutics 
devoted to the design and evaluation of DDSs, that release a drug at a rhythm to match 
the biological requirement for a given disease therapy.  
It has been found out that circadian rhythm is useful for the treatment of various 
pathophysiological conditions of human body, but such chronopharmacological 
phenomena are markedly influenced by not only the pharmacodynamics but also the 
pharmacokinetics of drugs. Thus, the application of circadian rhythm to pharmacotherapy 
may be accomplished by the optimal timing of the special formulation or DDS designed 
to synchronize drug concentrations to rhythms in disease activity.  
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The new chronotropic DDS technology for delivering drugs precisely in a time-controlled 
fashion in accordance with circadian rhythms may be developed as a 
chronopharmaceuticals product to treat different human diseases, as proposed by Fig.1 
  
 
 
 
 
 
 
 
 
 
  
 
 
 
Fig.1: Design and development of new chronotropic DDSs in accordance with circadian 
rhythm of human body. 
 
Rationale behind designing these chronotropic DDSs is to release the drug at desired time 
based on pathophysiological need of disease, which results in the improvement of 
therapeutic efficacy and patient-compliance. These systems are meant for treatment of 
those diseases that are caused due to circadian changes in body but the zero-order drug 
released products seem to have no desire.   
1.5.2. Biological rhythms and pulsatile hormone secretion
7, 8, 11
  
Biological rhythms exist in all living organisms, and may be necessary for survival under 
changing environmental conditions. The interval of biological rhythms can vary 
considerably according to the type of living organism. Some biological rhythms are very 
fast while others can be very slow, and many normal human biological functions exhibit 
predictable cyclic rhythms.   
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Ultradian rhythms
11
: Oscillations of shorter duration are termed Ultradian rhythms 
(more than one cycle per 24 hours) E.g. 90 minutes sleep cycle. 
Infradian rhythms
11
: Oscillations that are longer than 24hrs are termed as Infradian 
rhythms (less than one cycle per 24 hours) e.g. menstrual cycle. 
A biological clock exists in the brains of all mammals, and provides circadian 
information to all cells in the body, thereby allowing animals to adjust their physiology 
according to the time of day.  
Circadian rhythm
7, 8
  
Circadian rhythms can change the sleep-wake cycles, hormone release, body temperature, 
and other important bodily functions driving the alteration of various physiological, 
biochemical and behavioral processes (Fig. 2) 
 
Fig. 2: Human circadian time structure-dependent pulsatile hormones secretion 
 
 Pulsatile hormone secretion  
Many hormones in the human body are secreted in a cyclical or pulsatile manner, rather 
than continuously.   
Secretions of the anterior and posterior pituitary hormones, adrenal glucocorticoids, 
mineralocorticoids and catecholamine’s, gonadal sex steroids, parathormone, insulin, and 
glucagon are pulsatile.  
During hormone secretion, a baseline release is combined with the pulsed release. Insulin 
is one good example of a pulsatile hormone release.   
Pulsatile release of gastrointestinal hormones, stimulated by presence of food in the 
gastrointestinal tract, generally causes the release of digestive enzymes from the pancreas 
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and stomach. Many hormones including follicle stimulating hormone (FSH), luteinizing 
hormone (LH), luteinizing hormone releasing hormone (LHRH), estrogen, and 
progesterone are also regulated in the body in pulsatile manner. Numerous biological 
functions in the body are thus regulated by the temporal and pulsatile release of 
hormones.  
If the hormones were continuously secreted, a hormonal imbalance may arise, which 
would not only induce down regulation of hormone receptors on the target cellular 
membranes, but might also produce undesired side-effects.  
 
1.5.3. Circadian variation
7, 8, 16 
 
Circadian rhythm regulates several body functions such as metabolism, physiology, 
behavior, sleep patterns, hormone production, and so on.   
The circadian rhythm not only affects most physiological functions but also influences 
the absorption, distribution, metabolism, and elimination (ADME) of drugs, leading to 
changes in drug availability and target cell responsiveness Thus, the time-dependent 
dynamic bioprocesses in human body are significantly dependent on circadian variations, 
and so constant delivery of a drug into the human body seems both unnecessary and 
undesirable.   
Timing the administration of some medications in accordance with the body's 
circadian rhythm may significantly affect the drug's pharmacokinetics and 
pharmacodynamics (Fig. 3).   
Many common diseases also display a marked circadian variation during onset or 
exacerbation of symptoms, as shown in Fig.4.  
Since the circadian rhythm influences normal biological processes, the occurrence 
or intensity of symptoms of these diseases is not constant throughout the day.   
Several diseases, including arthritis, asthma, allergies, peptic ulcer disease, dyslipidemia, 
and cancer exhibit predictable circadian variation. Medications and treatments given at 
the appropriate time according to the body's circadian rhythms will result in more 
favorable outcomes. 
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Fig. 3: Effect of circadian rhythms on the ADME of drugs. 
 
 
Fig. 4: The circadian pattern of disease 
 
1.6. Pulsatile Drug Delivery system
7, 8, 10, 11, 17
 
 .  The pulsatile drug delivery system (PDDS) is intended to deliver a rapid, or 
transient, and quantified medication release after a predetermined off-release period (lag 
time). PDDS can deliver the correct amount of medication at the desired location at the 
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optimal time for maximum effect against disease, thereby enhancing therapeutic efficacy 
and improving patient compliance.  
PDDS avoids problems with degradation of drugs in the stomach or first-pass 
metabolism, enables the simultaneous administration of two different drugs, allows the 
release drugs at different sites within the gastro-intestinal tract, and can deliver a drug 
release burst at one or more predetermined time intervals, according to patient 
requirements.  
The advantages of PDDS extend to drugs with chronopharmacological behaviors, where 
nighttime dosing is required, and for various diseases that are influenced by circadian 
rhythms. Since PDDS has a unique mechanism of delivery, whereby a drug releases 
rapidly after a lag time, various PDDSs have appeared on the markets that replace 
modified-release dosage forms. Various release patterns are illustrated in Fig. 5. 
 
Fig. 5: Different release patterns for various pharmaceutical dosage forms 
The PDDS is formulated to release a drug after a predetermined lag time in a specific 
region of the gastrointestinal tract, or as a chronotherapeutic time-dependent release. 
Pulsatile drug release should occur independently of the environment (e.g. pH, enzymatic 
activity, intestinal motility) or other stimuli; lag time prior to the release of the drug is 
primarily determined by the formulation's design.  
 
1.6.1. Advantages of PDDS
18, 20, 21
  
 Nearly constant drug levels at the site of action.  
 Avoidance of undesirable side effects.  
 Reduced dose.  
 Improved patience compliance.  
 Used for drugs with chronopharmacological behavior.  
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 No risk of dose dumping.  
 Improved bioavailability, tolerability and reduces side effects.  
 
1.6.2. Limitations of PDDS
18, 20, 21
 
 Lack of manufacturing reproducibility and efficacy.  
 Large number of process variables.  
 Multiple formulation steps. 
 Higher cost of production.  
 Need of advanced technology.     
 Trained/ skilled personal needed for manufacturing. 
 
1.6.3. Mechanism of drug release from pulsatile drug delivery system
20
  
The mechanism of drug release from PDDS can be occurring in the following ways:  
Diffusion  
Water diffuses into the interior of the particle when particle come in contact with 
aqueous fluids in the gastrointestinal tract and resultant drug solutions diffuse across the 
release coat to the exterior.  
Erosion  
Some coatings designed to erode gradually with time, result in the release of drug 
contained within the particle.  
Osmosis  
An osmotic pressure can be built up within the interior of the particle when water 
allows entering under the right circumstances. The drug is forced out of the particle into 
the exterior through the coating. 
 
1.6.4. Methodologies for PDDS
17, 20
 
Methodologies for the PDDS can be broadly classified into four classes;  
 I. Time Controlled Pulsatile release   
A. Single unit system   
B. Multi-particulate system  
 II. Stimuli induced   
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A. Thermo-Responsive Pulsatile release 
B. Chemical stimuli induced pulsatile systems   
III. External Stimuli Pulsatile release   
A. Electro responsive pulsatile release    
B. Magnetically induced pulsatile release   
IV. Pulsatile release systems for vaccine and hormone products 
 
1.6.5. Disease treatments requiring pulsatile drug delivery
8, 9, 16
 
1.6.5.1. Normal physiological condition  
The body varies greatly in physiological and biochemical status over a 24-hour 
period due to circadian rhythm. Variation may be expressed as sleep-wakefulness, 
changes in body temperature, cell division, heart rate, and other factors (Fig. 2).   
Normal lung function undergoes circadian changes that reach a low level during the early 
morning hours. Endocrine substances, such as growth hormones, gonadotropins, and 
insulin are secreted from glands and organs in a pulsatile fashion, according to circadian 
rhythms, which maintain the normal condition of human life. The secretion of growth 
hormone reaches peak rates during sleep, but the plasma levels of both testosterone and 
cortisol are typically greatest in the early morning.  
1.6.5.2. Disease status
8
 
Variation in the severity of many diseases over a 24-hour period is well known. 
Diseases such as bronchial asthma, myocardial infarction, angina pectoris, rheumatic 
disease, ulcers, diabetes, attention deficit syndrome, hypercholesterolemia and 
hypertension show symptomatic changes due to circadian rhythmicity.   
Table 1: Diseases that require pulsatile drug delivery
18
 
Disease Chronological behavior Drugs used 
Peptic ulcer 
Acid secretion is high in the afternoon and 
at night. 
H2 blockers 
Cancer 
The blood flow to tumors is threefold 
greater during each daily activity phase of 
the circadian cycle than during the daily 
rest phase 
Vinca alkaloids, 
Taxanes 
Duodenal ulcer 
Gastric acid secretion is highest at night, 
while gastric and small bowel motility and 
Proton pump inhibitors 
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gastric emptying are all slower at night. 
Neurological 
disorders 
The central pathophysiology of epilepsy 
and the behavioral classification of 
convulsive events. 
MAO-B inhibitors 
Hypercholesterol
emia 
Cholesterol synthesis is generally higher 
during night than day time. 
HMG CoA reductase, 
Inhibitors 
Diabetes mellitus 
Increase in the blood sugar level after 
meal. 
Sulfonylurea, Insulin 
Arthritis Level of pain increases at night. 
NSAIDs, 
Glucocorticoids 
Cardiovascular 
diseases 
BP is at its lowest during the sleep cycle 
and rises steeply during the early morning. 
Nitroglycerin, calcium 
channel, blocker, ACE 
inhibitors 
Asthma 
Precipitation of attacks during night or at 
early morning 
Β2 agonist, 
Antihistamines 
Attention deficit 
syndrome 
Increase in DOPA level in afternoon. Methylphenidate 
 
Thus, understanding the biological basis of these changes over the day and during 
the night can help to enhance drug therapy, by identifying appropriate times for drug 
administration. 
 
1.6.6. Polymers used in PDDS
15
 
 Hydroxypropyl methyl cellulose (HPMC) 
 Ethyl cellulose 
 Cellulose Acetate Phthalate 
 Eudragit 
 Hydroxypropyl cellulose (HPC) 
 Xanthan gum 
 
1.7. FLOATING PULSATILE DRUG DELIVERY SYSTEM
14
 
 The combinations of floating and pulsatile principle are very well suitable for site 
and time specific oral drug delivery has recently been of greater interest in 
pharmaceutical field to achieve improved therapeutic efficacy. 
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1.7.1. Advantages
14 
 Prolonged retention of drug delivery system in stomach 
 To increase drug bioavailability, predictable, reproducible and improved 
generally short gastric residence time, no risk of dose dumping local drug action 
and the flexibility to blend dosage form with different composition and release 
pattern. 
 To keep the drug in floating condition in stomach to get relative better response. 
1.7.2. Disadvantages
14
 
 Manufacturing of dosage form requires multiple formulation steps and higher cost 
of production. 
 The dosage form should be administered with full glass of water. 
 Drugs which are irritant to gastric mucosa is not desirable or suitable. 
 
1.7.3. Design of floating pulsatile drug delivery system (FPDDS) 
14
 
 
 
  
 
 
A- Rapid release core tablet B- Hydrophilic polymer C- Buoyant layer 
Fig. 6: Schematic diagram of floating pulsatile drug delivery 
A 
A 
B B 
C 
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FLOATING PULSATILE DRUG DELIVREY 
S. C. Jagdale et al.
22
 developed the press coated floating pulsatile drug delivery of 
Lisinopril for the treatment of hypertension. In this formulation, the core tablet was 
formulated using the Superdisintegrants crospovidone and croscarmellose sodium. A 
press coated tablet contained the polymer carrageenan, xanthan gum, HPMC K4M, and 
HPMC K15M. The buoyant layer was optimized with HPMC K100M, sodium 
bicarbonate and citric acid. 5% superdisintegrant showed good results. The formulation 
containing xantham gum showed drug retaining properties and failed to float. The tablet 
containing HPMC K15M showed a high swelling index. The lag time for the tablet 
coated with 200 mg carrageenan was 3±0.1 hrs with 99.99±1.5 % drug release; with 140 
mg HPMC K4M, the lag time was 3±0.1 hrs with 99.71±1.2 % drug release; and with 
120 mg of HPMC K15M, the lag time was 3±0.2 hrs with 99.98±1.7 % drug release. The 
release mechanism of the tablet followed the Korsmeyer-Peppas equation and first order 
release pattern. 
 
Mishra et al.
23
 formulated a dry coated floating pulsatile drug delivery system of 
Enalapril maleate in the treatment of hypertension. The dry coated tablet consists in a 
drug containing core, coated by a hydrophilic erodible polymer (HPMC E50 and lactose) 
which is responsible for a lag phase in the onset of pulsatile release. The Buoyant layer 
consists of Methocel E50, Carbopol 934P and sodium bicarbonate. Results reveal that 
coating composition affects the lag time. Formulation containing lactose as filler with 
6.67% crospovidone and coating composition using 30% lactose provide lag time of 4 hr 
with 93.03% drug release in 6 hr that shown a sigmoidal release pattern. 
 
S.C Jagdale et al.
24
 developed the compression coated floating pulsatile drug 
delivery of Bisoprolol. The system consisted of two parts core tablet containing active 
ingredient and erodible outer shell with gas generating agent. Rapid release core tablet 
was prepared using superdisintegrant with active ingredient which is then press coated 
with the polymer. A 3
2  
full factorial design was used for optimization. The amount of 
polyox WSR205 and polyox WSR N12K was selected as independent variables. Lag 
period, drug release and swelling index was selected as dependant variables. Floating 
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pulsatile release formulation F13 at level 0 (55mg) for polyox WSR205 and level +1 
(65mg) for polyox WSR N12K showed a lag time of 4 hr with more than 90% drug 
release. Release kinetics of the optimized formulation best fitted the zero order model. 
 
Anuradha K.Salunkhe et al.
25
 formulated the floating pulsatile drug delivery 
system of Metoprolol tartrate for the treatment of morning surge of hypertension. The 
rapid release core tablet (RRCT) was prepared by using Superdisintegrants along with 
active ingredient. The dry coating of optimized RRCT was done by using different grades 
of HPMC E15, E5, E50 and uppermost buoyant layer was prepared with HPMC K15M 
and sodium bicarbonate. The results reveal that FPRT F9 showed a floating lag time of 4 
minutes and floating time of 112 hrs and release lag time of 6 hrs. 
 
Raja et al.
26
 developed the floating pulsatile drug delivery system of Metoprolol 
succinate intended for chronopharmacotherapy of hypertension. The dry coated system 
consisting of drug containing core, coated with hydrophilic erodible polymer (HPMC E5, 
E15, E50), which is responsible for lag phase of pulsatile release, top cover buoyant layer 
prepared with HPMC K4M and sodium bicarbonate. FPRT containing the floating 
material HPMC K4M and NaHCO3 (80:20) showed a lag time less than 1 min and 
floating time more than 12 hrs. FPRT prepared using HPMC E50 (200 mg) showed a 
satisfactory lag time and drug release. 
 
Gagganapalli Santhoshi Reddy et al.
27
 prepared the Gastroretentive pulsatile 
release tablets of Lercanidipine HCl to enhance bioavailability and treat early morning 
surge in blood pressure. Immediate release core tablets containing lercanidipine HCl were 
prepared and optimized core tablets were compression-coated using buoyant layer 
containing polyethylene oxide (PEO) WSR coagulant, sodium bicarbonate and directly 
compressible lactose. DoE optimization of data revealed FPRTs containing PEO (20% 
w/w) with coat weight 480 mg were promising systems exhibiting good floating behavior 
and lag time in drug release. Abdominal X-ray imaging of rabbits after oral 
administration of the tablets, confirmed the floating behavior and lag time. A quadratic 
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model was suggested for release at 7
th
 and 12
th
 hr and a linear model was suggested for 
release lag time. 
 
Swati C. Jagdale et al.
28
 worked on Application of Design of Experiment for 
Polyox and Xanthan gum coated floating pulsatile delivery of Sumatriptan succinate in 
migraine treatment. Burst release was achieved through immediate release tablet using 
crospovidone as superdisintegrant (10%). Pulse lag time was achieved using swellable 
polymer polyox WSR205 and xanthan gum. 3
2
 experimental design was applied. The 
results revealed that optimized formulation F8 containing polyox WSR205 (72.72%) and 
xanthan gum(27.27%) of total weight of polymer has shown floating lag time of 55±2 
sec, drug content of 100.35±0.4%, hardness of 6±0.1Kg/cm
2
, and 98.69±2% drug release 
in pulse manner with lag time of 7±0.1 hr. Optimized formulation showed prolong gastric 
residence which was confirmed by invivo X-ray study. 
 
Sunil Patel et al.
29
 designed and developed the floating pulsatile drug delivery 
system of meloxicam for the treatment of rheumatoid arthritis and osteoarthritis. The 
rapid release core tablet (RRCT) was prepared by using Superdisintegrants along with 
active ingredient. Dry coating of optimized RRCT was done by using different grades of 
HPMC (E5, E15, E50) and upper most buoyant layer was prepared with HPMC K15M 
and sodium bicarbonate. The developed formulations were evaluated. The results 
revealed that floating pulsatile release tablet F8 showed floating lag time of 4 min, 
floating time of 12 hrs and release lag time of 6 hrs. The optimized formulation showed 
compliance with chronotherapeutic objective of rheumatoid arthritis. 
 
Zou et al.
30
 worked on design and evaluation of a dry coated drug delivery system 
with floating pulsatile release of verapamil. The dry coated tablet consists in a drug 
containing core, coated by a hydrophilic polymer (HPMC E15) which is responsible for a 
lag phase in the onset of pulsatile release. The buoyant layer, prepared with Methocel 
K4M, carbopol 934P and sodium bicarbonate provides buoyancy to increase the retention 
of the oral dosage form in the stomach. Developed formulations were evaluated for their 
buoyancy, dissolution and pharmacokinetic, as well gamma-scintigraphically. The results 
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showed that a certain lag time before the drug released generally due to the erosion of the 
dry coated layer. Floating time was controlled by the quantity and composition of the 
buoyant layer. Both pharmacokinetic and gamma-scintigraphic data point out the 
capability of the system of prolonged residence of the tablets in the stomach and releasing 
drugs after a programmed lag time. 
 
Swati C. Jagdale et al.
31
 formulated and evaluated the floating pulsatile drug 
delivery system of Atenolol. The rapid release core tablet (RRCT) of drug was prepared 
with croscarmelllose sodium and KYRON T314.  RRCT then compression coated with 
erodible outer shell- HPMC K4M, HPMC E15 LV, carboxymethyl cellulose sodium. The 
buoyant layer was prepared with HPMC K100M, sodium bicarbonate and citric acid. 
Developed formulations were evaluated. The results showed that K3 (180mg HPMC 
K4M) and K6 (290mg of HPMC E15LV) with a buoyant layer were the best formulations 
with the lag times of 5.2±0.1 hr and 4.1±0.2 hr. 
 
Galgatte et al.
32
 studied the floating pulsatile drug delivery of ranitidine 
hydrochloride for nocturnal acid breakthrough: design, optimization, in-vitro and in-vivo 
evaluation. The core tablet was prepared with the drug by direct compression, which was 
coated with ethyl cellulose (EC N10) and hydroxypropyl methyl cellulose (HPMC E15) 
followed by coating of HPMC E15and sodium bicarbonate for generation of 
effervescence which was further coated by eudragit RL 100 for effervescence entrapment 
to produce density <1. Optimization was done by central composite design (CCD). The 
results showed that ratio of EC N10 and HPMC E15 (80:20%w/w) was optimized which 
provide drug release 97.56% in pulsatile manner with a lag time of 3 to 3.5 hr. HPMC 
E15 and sodium bicarbonate (1:4%w/w) provide floating lag time of 5 min. Eudragit 
RL100 (5%  w/w) provide good floating property. 
 
A. Shahiwala et al.
33
 worked on statistical optimization of ranitidine HCl floating 
pulsatile delivery system for chronotherapy of nocturnal acid breakthrough. In this study, 
investigation of the functionality of the outer polymer coating to predict lag time and 
drug release was statistically analyzed using the response surface methodology (RSM). 
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Percentage weight ratios of ethyl cellulose to hydroxypropyl methyl cellulose in the 
coating formulation and coating level (% weight gain) were optimized with a 3
2
 full 
factorial design. The coating formulation containing EC ad HPMC in percentage weight 
ratio of 78.75:21.25 at 7% coating level was in the optimum zone and has the potential 
for time-controlled pulsatile delivery of ranitidine. 
 
Piyush Patel et al.
34
 formulated and evaluated the floating drug delivery system of 
famotidine. Floating core tablet was prepared, which is pan coated with EC and HPMC. 
Optimization done by using response surface methodology and 3
2 
factorial design. The 
optimized coating level %weight gain was 7.50% and percentage weight ratio of ethyl 
cellulose to hydroxypropyl methyl cellulose was 78.50% that provide lag time of 218 
minute and drug release of 88.21% with minimum percentage error with predicted values 
from the software. 
 
Shinde PV et al.
35
 formulated and evaluated the floating press-coated pulsatile 
release of aceclofenac tablets for the treatment of rheumatoid arthritis. The core tablets 
were prepared by direct compression with drug and different concentration of sodium 
starch glycolate, which is then compression coated with hydroxypropyl methyl cellulose 
and sodium bicarbonate. The results showed that dry coated formulations F15 (27.5% of 
HPMC K4M), F18 (25% of HPMC K15M) and F22 (25% of HPMC K100M) shows 8 hr 
floating with pulsatile release pattern. 
 
Zine et al.
36
 developed single unit floating pulsatile site specific drug delivery 
system for chronotherapeutic release of aceclofenac. In this method, triple layer tablet 
and dry coated tablet of aceclofenac were prepared and compared for pulsatile release. 
The trilayer consisted of floating layer, drug containing layer and polymer layer. The core 
tablet containing was prepared and dry coated with different percentage of polymers. The 
results revealed that dry coating of drug provides pulsatile release pattern. The polymer 
coating level and amount of polymer plays a major role in buoyancy and pulsatile release 
pattern. 
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N. Tejaswini et al.
37
 formulated and Evaluated the Floating Pulsatile Tablet of 
Eprosartan. Floating pulsatile tablets were formulated by compression coating technique 
containing active ingredient, croscarmellose sodium, microcrystalline cellulose, 
magnesium stearate in the core, ethyl cellulose and different grades of hydroxypropyl 
methyl cellulose in an erodible outer shell, sodium bicarbonate and HPMC K15 in the top 
buoyant layer. The results showed that the thickness of the outer coat and core: polymer 
ratios significantly affect the lag time and drug release. Change in viscosity grade of 
polymer altered the lag time along with its swelling index in an order: HPMC E50 > 
HPMC E15 >HPMC E5. Floating time was controlled by the quantity and composition of 
buoyant layer. 
 
Rajesh Asija et al.
38
 formulated and evaluated the floating pulsatile drug delivery 
for chronotherapy of hypertension. Nifedipine floating beads were prepared by ionotropic 
cross linking method using acidified calcium chloride as cross linking agent. Various 
process parameters like drug: polymer ratio, amount of sodium bicarbonate, 
concentration of calcium chloride, concentration of acetic acid were optimized to get the 
required lag time and release. The optimized formulation A11 showed 83.79% drug 
entrapment, 79% buoyancy, 6 hrs lag time with 7.31% drug release. 
 
M. S. Sokar et al.
39
 formulated and evaluated the pulsatile core-in-cup valsartan 
tablet. Core tablets were prepared by direct compression of homogenous mixture of 
valsartan and croscarmellose sodium. Core in cup tablets were formulated using different 
polymers as a plug layer, including sodium alginate (SA), Sodium carboxymethyl 
cellulose (NaCMC) and hydroxypropyl methyl cellulose (HPMC). The results showed 
that the release lag time of the tablets increased when the quantity of the plug layer 
increased thus decreasing the drug release. Plug layer polymers showed a lag time with 
rank order: SA < NaCMC < HPMC. The optimized formulations F5 (having SA as plug 
polymer) released drug after a lag time of 2 hr while F6 released the drug in two 
successive pulses with a reasonable lag time in between due to its floating behavior. 
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Shaji Jessy et al.
40
 formulated and optimized the floating pulsatile aceclofenac 
microspheres using response surface methodology. The floating pulsatile microspheres 
were prepared by emulsion solvent diffusion technique. A 3
2
 factorial design was 
employed to study the effect of independent variables, drug to polymer ratio and stirring 
speed, on dependent variables, particle size and drug entrapment efficiency. The 
optimized batch (Drug to polymer ratio of 1:3 and stirring speed of 500 rpm) showed 
high entrapment efficiency of 90.1% and mean particle size 118.66µm. The floating 
microsphere provides two phase release pattern with initial lag time during floating in 
acidic medium followed by rapid release in phosphate buffer. 
 
Shinde et al.
41
 developed and evaluated the floating pulsatile release tablet of 
aceclofenac. Triple layer tablet was prepared using hydrophilic polymer (HPMC K4M) as 
bottom layer and hydrophobic polymer (EC) as top layer. The formulation F8 possessed 
good floating property with floating time 470minutes and showed pulsatile drug delivery 
pattern. 
 
Kshirsagar et al.
42
 optimized the floating pulsatile drug delivery system for 
chronotherapy of hypertension. The floating beads were prepared by simple process of 
acid-base reaction during ionotropic cross linking by low viscosity sodium alginate and 
calcium chloride as a cross linking agent. The functionality of the sodium alginate to 
predict lag time and drug release was statistically analyzed using the response surface 
methodology (RSM). The chosen independent variables, i.e. sodium alginate and 
potassium bicarbonate were optimized with a 3
2
 full factorial design.  The results 
revealed that the optimized formulation prepared according to computer-determined 
levels provided a release profile, which was close to the predicted values. The ﬂoating 
beads obtained were porous (21-28% porosity), hollow with bulk density <1 and had 
Ft70 of 2–11 h. The ﬂoating beads provided expected two-phase release pattern with 
initial lag time during ﬂoating in acidic medium followed by rapid pulse release in 
phosphate buffer. 
 
LITERATURE REVIEW 
 
Department of Pharmaceutics, Madras Medical College Page 27 
 
Shivhare et al.
43
 developed and evaluated the floating pulsatile microspheres of 
metoprolol tartrate using emulsification-solvent evaporation technique. Polymers used for 
the preparation were Eudragit L 100 and Eudragit S 100. The floating microspheres 
provided two phase release pattern with initial lag time during floating in acidic medium 
followed by rapid release in phosphate buffer. The optimized formulation G3 containing 
drug: polymer ratio (1:2), span 80 (2% w/v) and Sodium bicarbonate (1.5%w/v) showed 
95% of drug release for 9 hrs and particle size of 803.3µm and follow Korsmeyer-Peppas 
model in dissolution studies. 
 
Jain et al.
44
 formulated and evaluated the floating pulsatile drug delivery system 
for chronotherapy of rheumatoid arthritis. The system developed consists of drug 
containing core tablets, which were coated with pH-dependent polymer Eudragit S100 
and outer effervescent layer of polymers and sodium bicarbonate showed floating in 
acidic medium with no drug release followed by rapid release of drug in basic medium. 
The results showed that formulation FPRT II (40% HPMC K 100M) with no drug release 
for 6-7 hrs followed by rapid and burst release of drug. 
 
PULSATILE DRUG DELIVERY 
Kamat Akshay Ramesh et al.
45
 formulated and evaluated the pulsatile drug 
delivery system containing indomethacin using natural polymers. The press-coated 
pulsatile release tablet contains drug in the inner rapid core tablet formulated by direct 
compression method using plantago ovata mucilage and modified agar as 
Superdisintegrants and the external coat formulated using natural polymers such as 
dammar gum, chitosan, xanthan gum and guar gum by both direct and wet granulation 
method. The prepared tablets were evaluated. Formulation A1, A8, B2 and B7 were 
selected as best formulations. The formulation B2 prepared by wet granulation method 
containing xanthan gum and dammar gum in the ratio of 2:1 showed maximum lag time 
of  7hr and 15 min, highest swelling index of 89.44% and cumulative percentage drug 
release of 99.29% at the end of 10hr. 
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Kumar et al.
46
 formulated and Evaluated the Two-Pulse Drug Delivery System of 
Amoxicillin Trihydrate. The core tablets were compressed and coated with 
hydroxypropyl methylcellulose (HPMC) of different viscosities with spray-dried lactose 
(SDL) as a pore former. The final two-pulse release tablet was prepared with the 
remaining drug fraction (to be released as the first immediate release pulse) with a 
disintegrant, giving the final tablet. The tablets were evaluated. The results showed that 
the core tablet disintegrated within 30 to 40sec and drug content ranged from 97.85 to 
98.23%. In vitro drug release showed prolongation of lag time as polymer viscosity 
increased. With 25 % HPMC and 75 % SDL, drug release was 97.5 % by the end of 8th, 
9th &10th hr and viscosity was 100, 400 and 4000 cps respectively. 
 
Aggarwal et al.
47
 formulated and optimized the chronotherapeutic drug delivery 
of Carvedilol sulphate compression coated tablets by using design of experiment 
approach. Optimization done by response surface methodology based on 3
2
 factorial 
designs. Compression coated tablet containing carvedilol phosphate in the core was 
formulated with an outer coat by eudragit L 100 and ethyl cellulose. The percentage 
weight ratio of ethyl cellulose to eudragit L 100 and coating level were selected as critical 
process parameters (CPPs), whereas critical quality attributes (CQAs) were lag time and 
cumulative percentage drug release at 8 hr in current study. The optimized formulation 
with 19.34 % ratio of ethyl cellulose with eudragit L 100 at 31.03 % coating level showed 
267 minute lag time and 76.2 %  cumulative drug release after 8 hr. 
 
Sayantan Mukhopadhyay et al.
48
 formulated and evaluated the Pulsatile drug 
delivery system for sequential release of Atorvastatin. The core tablets of Atorvastatin 
were prepared by direct compression technique using SSG as super disintegrants. Then 
the core tablets are coated with the different concentrations of polymers such as Eudragit 
RS 100, Eudragit S 100, Ethyl cellulose, CAP, HPC. All prepared multilayered tablets 
were subjected for evaluation parameters. In-vitro drug release profiles of the prepared 
tablets were suggested that, the release of drug from compression coated tablets match 
with chronobiological requirement of disease. 
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P. Shafi et al.
49
 formulated and evaluated the pulsatile drug delivery system of 
lansoprazole by using press coated method. The core tablet of lansoprazole was prepared 
with different concentrations of sodium starch glycolate. The optimized core tablet was 
then compression coated different ratios of Klucel EXF and EC N20. The prepared 
tablets were evaluated. The results revealed that F2 formulation with ratio Klucel EXF: 
EC N20 (87.5:12.5) showed 6 hr release. From the work, it was concluded that, press 
coating is necessary to provide pulsatile release. The polymer coating level and quantity 
of polymer played a main role for providing pulsatile release pattern. 
 
Patil B S et al.
50
 developed and evaluated the time controlled pulsatile release 
Lisinopril tablets. The core containing Lisinopril was prepared by direct compression 
method and evaluated. The coating materials consisted of hydrophobic polymer of ethyl 
cellulose and hydrophilic materials (HPMC 15 CPS) were used in different concentration.  
The optimized formulation (HPMC 15 CPS-150mg and EC-100mg) showed good lag 
time with drug release of 99.10%. From the results, it was concluded that the prepared 
pulsatile drug delivery system is suitable for chronotherapeutic management of 
hypertension. 
 
Singh et al.
51
 designed and evaluated the compression coated pulsatile release 
tablets of Losartan potassium. Two types of core tablets were prepared by direct 
compression, one containing superdisintegrant crospovidone(C) and other containing 
effervescent agent (E) for producing burst release.  The core tablets were compression 
coated with three different polymers i.e. sodium carboxymethyl cellulose R(NaCMC), 
HPMC K4M and HPMC E50. It was found that core tablets containing superdisintegrant 
failed to produce burst drug release pattern while effervescent agent was able to do so. 
Results also reveal that coating composition and coating level affects lag time. 
Formulation containing effervescent agent in core and coated with 200mg hydroxypropyl 
cellulose provide lag time of 4.5 hr with 73% drug release in 6 hr that followed a 
sigmoidal release pattern. These values were close to the desired objective of producing 
lag time of 5-6 hr followed by fast drug release. 
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Krishnaveni.G et al.
52
 developed and evaluated the pulsatile drug delivery system 
of Montelukast sodium by press coated tablet using natural polysaccharides. The core 
tablet was prepared by direct compression with different concentrations of 
Superdisintegrants. The core tablet was then coated with a natural polymers such xanthan 
gum, guar gum and mixture of it. The prepared tablets were evaluated. The formulation 
P5F3 was optimized with the drug release of 92.8% at the end of 10
th
 hr and follows 
peppas model with R
2
 of 0.983. 
 
Kumud Upadhyaya et al.
53
 Developed and evaluated the nifedipine pulsatile tablet 
for colon drug delivery. The core tablet of nifedipine was prepared by wet granulation. 
The core tablet was compression coated with polymer blend of ethyl cellulose (water 
insoluble polymer) and Eudragit L 100 (Enteric polymer). The results revealed that the 
formulation having a coating level of 50% w/w of core and weight ratio of ethyl cellulose 
to Eudragit L 100 (20%) showed lesser release profile as compared to other formulation 
i.e. 52.83% in 12hrs. As we increase the weight ratio of ethyl cellulose to Eudragit L 100 
better entrapment of drug leading to controlled release of drug.  
   
Patel Tejaskumar et al.
54
 formulated and evaluated the erodible pulsatile drug 
delivery system of Salbutamol sulphate for Nocturnal asthma. The core tablet was 
prepared by direct compression. The core tablet is coated with the different 
concentrations of inner swellable polymer HPMC E5. The prepared tablet again enteric 
coated with 5% cellulose acetate phthalate. Salbutamol sulphate coated with 30% HPMC 
E5 layer then by 5% CAP coating solution was optimized. 
 
Singh et al.
55
 developed and evaluated the pulsatile drug delivery system of 
Aceclofenac sodium. The core tablet was prepared with the drug and varying 
concentrations of Superdisintegrants. The core tablet was compression coated with 
different ratio of ethyl cellulose (EC) and HPMC K4M. The optimized tablet was then 
enteric coated with cellulose acetate phthalate solution. Formulation C5 containing 
HPMC K4M & EC (20:80) was found to provide maximum lag time of 5hrs and thus, 
enteric coated with 3% CAP (cellulose acetate phthalate) solution, so as to increase the 
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lag time and minimize the variability in gastric region. The CAP coated formulation 
showed lag time of 7 hrs and 98% drug release. 
 
D. Pavani et al.
56
 developed and evaluated the Metoprolol tartrate 
chronotherapeutic drug delivery system. The core tablets were prepared by using various 
concentrations of Superdisintegrants, the formulated core tablets were compression 
coated with the polymers (EC N50 and HPMC K100M). The core and press coated 
tablets were evaluated. The results revealed that C5 and C9 showed maximum drug 
release after 8th hr. Time dependent pulsatile drug delivery system has been achieved 
from tablet of formulation C5 and C9 with 98.37% and 99.9%.   
 
Janugade B. U. et al.
57
 formulated and evaluated the press coated Montelukast 
sodium tablets for pulsatile drug delivery system. The core tablet of Montelukast was 
prepared by direct compression. The core tablet is press coated with different 
compositions of hydrophobic polymer ethyl cellulose and hydrophilic polymer low-
substituted hydroxypropyl cellulose by both wet granulation and direct compression. The 
results revealed that lag time decreases with increasing concentration of low-substituted 
hydroxypropyl cellulose. Press coated tablets coated by dry mixing and by wet 
granulation showed variations in lag time. As compared to dry mixed blend method wet 
granulation method gives less lag time. 
 
Rajesh Asija et al.
58
 formulated and evaluated the pulsatile tablet of Ramipril. The 
core tablet of ramipril was prepared with croscarmellose sodium by direct compression. 
The optimized core is then press coated with the hydrophilic polymer HPMC K100M and 
hydrophobic polymer ethyl cellulose. The results obtained indicated that optimum 
amounts of HPMC K100M and ethyl cellulose more essential to produce pulsatile release 
tablets with desirable lag time and release characteristics. The combination of HPMC 
K100M and ethyl cellulose showed the synergistic effect on lag time. The finding 
indicates that the lag time of a press coated tablet can be modulated from 4 to 6 hrs by 
combining ethyl cellulose with HPMC K100M in different weight ratio. The release 
profile of optimized formulation of ramipril was close to korsmeyer peppas model. 
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CAPTOPRIL 
Gangane et al.
59
 formulated and evaluated the chronomodulated pulsatile 
therapeutic system for early morning surge in blood pressure. The core tablet was 
prepared using drug and different concentrations of croscarmellose sodium by direct 
compression method.  Core tablet was then press coated with different ratio of polymers 
(HPMC K4M and Ethyl cellulose).  From the results, it was concluded that the lag time 
decreases with increase in concentration of HPMC K4M. When the concentration of the 
hydrophilic polymer was increased, hydration property of the system increases, causing 
more rapid dissolution or rupturing of the external shell resulting in the reduction of lag 
time. 
 
Sameer Singh et al.
60
 formulated and evaluated the floating tablet of Captopril. 
The floating tablets were prepared using different grades of hydroxypropyl methyl 
cellulose (HPMC K4M, K15M and K100M). Lactose and citric acid were used in 
different concentration as a channeling and chelating agent. Results revealed that the 
effect of channeling and chelating agent at different concentration had significant effect 
on the release of the drug from hydrophilic matrix tablet. Different viscosity grades of 
HPMC influence the drug release from the hydrophilic matrix and also affect the floating 
property. 
 
Patil B. S. et al.
61
 formulated and evaluated the floating matrix tablets using 
HPMC 50cps. The floating matrix tablets contained drug, a gas generating agent (6%-
18% of NaHCO3) and water soluble polymer (40%-60% of HPMC 50cps) was prepared 
by direct compression. The prepared tablets were subjected to hardness, friability, weight 
variation, thickness, drug content, lag time subsequently buoyancy time, and in-vitro 
dissolution studies. The optimized formulation C3 showed a drug release of 91.32% in 10 
hrs with floating lag time of 2min 27sec. 
 
Shahtalebi et al.
62
 formulated and evaluated the orally disintegrating tablets of 
Captopril using natural Superdisintegrants. The disintegrating Captopril tablets were 
prepared using croscarmellose sodium, crospovidone and two natural Superdisintegrants: 
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karaya gum and natural agar. A 3
2
 full factorial design was applied to optimize the 
formulation and 9 batches were prepared and evaluated. The results revealed that Karaya 
gum in the concentration of 9% w/w with Avicel PH 102 in 25% w/w gave rapid 
disintegration in 25sec and showed 100% drug release within 5 minutes, it was concluded 
that orally disintegrating tablets of captopril can be successfully formulated using karaya 
gum. 
 
Patil et al.
63
 developed and characterized the chronomodulated drug delivery 
system of captopril. The core tablet containing drug was prepared by direct compression 
method and then coated sequentially with an inner swelling layer containing hydrocolloid 
HPMC E5 and an outer rupturable layer consisted of Eudragit RL/RS (1: 1). The results 
showed that as the amount of inner swelling layer increases, the lag time decreases and as 
the Eudragit coating level increases, the lag time increases and percent water uptake of 
time-dependent pulsatile release system decreases. The presence of an osmotic agent and 
effervescent agent helped in shortening of lag time. 
 
Singla et al.
64
 formulated and evaluated the floating matrix tablets of captopril. 
The floating matrix tablets of varying concentrations of HPMC K15M, HPMC K4, 
chitosan and sodium bicarbonate (gas former) were prepared by direct compression. 
Floating capacity and drug release studies were conducted in 0.1 N HCl at 37 ± 0.5 0C.  
The matrix tablets revealed a gradual drug release during an 8 h period following a non-
Fickian diffusion process. The optimized batch with 30% wt. of HPMC K4M and HPMC 
K15M, showed floating lag time of 5-10 min whereas batch with 30% chitosan and other 
entire batches showed immediate floatation. From the results, it was concluded that 
floating matrix tablets holds a lots of potential for drug which are unstable in alkaline pH 
or are which mainly absorbed in acidic pH. 
 
Bolourtchian N et al.
65
 formulated and optimized the captopril sublingual tablet 
using D-optimal design. Captopril containing tablets were prepared by direct 
compression method using different ingredients such as polyvinyl pyrrolidone, starch 
1500, sodium starch glycolate and lactose (independent variables) and magnesium 
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stearate, talc and aspartame (fixed components). Tablets were evaluated for the physical 
properties including hardness, disintegration time and friability which were considered as 
responses in a D-optimal experimental plan. Results were statistically examined using 
special cubic model and polynomial mathematical equations and found to be statistically 
significant (p<0.05) for disintegration time and friability data. Meanwhile linear model 
was best fitted with hardness data. The obtained results were used to generate optimized 
overlay plot. The physical data from the numerical optimization were verified and found 
to be very close to those predicted from the regression analysis. Additional experiments 
including drug content, in vitro drug dissolution rate and accelerated stability studies 
were also performed on the optimum formulation. All results were in accordance with the 
requirements of a sublingual tablet. 
 
Z. Rahman et al.
66
 designed and evaluated the bilayer floating tablets of captopril. 
The bilayer tablets were prepared by direct compression. HPMC K-grade and 
effervescent mixture of citric acid and sodium bicarbonate formed the floating layer. The 
release layer contained captopril and various polymers such as HPMC-K15M, PVP-K30 
and Carbopol 934p. The floating behavior and in vitro dissolution studies were carried 
out in a USP 23 apparatus 2 in simulated gastric fluid (without enzyme, pH 1.2). In vitro 
dissolution studies showed controlled release of 95% for 24 h with floating lag time of 10 
min followed the Higuchi diffusion mechanism and in vivo studies indicated increased 
GRT. From the results, it was concluded that the captopril floating system was an 
alternative approach to the conventional dosage form.  
 
Vijayasankar G R et al.
67
 formulated and evaluated the captopril gastro-retentive 
floating drug delivery system. The tablets were prepared using drug with different grades 
of hydroxypropyl methyl cellulose and sodium bicarbonate by direct compression 
method. The prepared tablets were evaluated for floating lag time, floating time, swelling 
studies and invitro drug release. The results revealed that formulation F5 showed high 
swelling index with floating time more than 8hr with immediate floating lag time. 
Formulation F5 was optimized with the drug release of 96.22% at the desired time of 8hr. 
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Lingam Meka et al.
68
 prepared the matrix type multiple unit gastro retentive 
floating drug delivery systems for captopril based on gas formation technique: invitro 
evaluation. The system consisted of the drug-containing core units prepared by direct 
compression process, which were coated with three successive layers of an inner seal 
coat, effervescent layer (sodium bicarbonate) and an outer gas-entrapped polymeric 
membrane of an polymethacrylates (Eudragit RL30D, RS30D, and combinations of 
them). The results revealed that the time to float was decreased as amount of the 
effervescent agent increased and coating level of gas-entrapped polymeric membrane 
decreased. The optimum system floated completely within 3 min and maintained the 
buoyancy over a period of 12 h. The drug release was controlled and linear with the 
square root of time. 
 
Suman Rawat et al.
69
 formulated and evaluated the floating microspheres of 
Captopril. Floating microspheres were prepared by Non-aqueous solvent evaporation 
technique using Ethyl cellulose, Eudragit RS-100, Eudragit RL-100 polymers in varying 
concentration. Formulations were evaluated for percent yield, particle size, entrapment 
efficiency, in vitro buoyancy and in vitro drug release studies. Results revealed that F3 
and F9 showed no significant changes in percentage drug entrapment efficiency, particle 
size, percentage buoyancy and in vitro controlled release of Captopril. The optimized 
formulation F3 and F9 follows zero order, non fickian diffusion mechanism. 
 
Hisakazu Sunada et al.
70
 prepared and evaluated the captopril elementary osmotic 
pump tablets. The core tablet was prepared using drug, microcrystalline cellulose, sodium 
chloride and HPMC K15by wet granulation. The core tablet was coated with cellulose 
acetate solution by pan coating. An orifice was drilled in the centre of each coating tablet 
by micro drill. In the drug release study in vitro, the influence of the tablet formulation 
variables, the amount of NaCl, hydroxypropyl methylcellulose K15 (HPMCK15), 
microcrystalline cellulose (MCC) in the core, the concentration of cellulose acetate (CA), 
dibutylphthalate (DBP), and polyethylene glycol 400 (PEG-400) in the coating solution 
have been investigated. From the results, it was found that the drug release was mostly 
affected by the amount of NaCl, HPMCK15, and MCC in the core, and the amount of 
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PEG-400 in the coating solution. To a certain extent, drug release was less affected by the 
orifice size, concentration of coating solution, and the coating weight. It was also 
independent of the pH of the dissolution medium and orifice quantum. The drug release 
mechanism has been shown to involve release kinetic derived from differences in the 
osmotic pressure across the membrane. The relative bioavailability of EOPT was 119.9%. 
EOPT showed a good correlation between absorption in vivo and drug release in vitro. 
 
Mohammed G Ahmed et al.
71
 formulated and evaluated the gastric mucoadhesive 
drug delivery systems of captopril. Gastro-retentive beads of captopril were prepared by 
orifice ionic gelation method in 1:1 and 9:1 ratio of alginate along with mucoadhesive 
polymers: hydroxypropyl methyl cellulose, carbopol 934P, chitosan and cellulose acetate 
phthalate. The prepared beads were subjected for various evaluation parameters. The 
results showed that Alginate-chitosan (9:1) beads showed excellent microencapsulation 
efficiency (89.7 percent). Alginate-Carbopol 934P exhibited maximum efficiency of 
mucoadhesion in 0.1N Hydrochloric acid (44% for 1:1 and 22% for 9:1) at the end of 8 
hours, whereas least mucoadhesion was observed with alginate-Cellulose acetate 
phthalate beads. The in vitro release studies were carried out in 0.1 N Hydrochloric acid 
and the release were found to be more sustained with Alginate-chitosan beads (9:1) than 
Alginate-Carbopol 934P (1:1) beads. The alginate-cellulose acetate phthalate beads 
showed the better sustained release as compared to all other alginate- polymer 
combinations. Regression analysis showed that the release followed zero order kinetics.  
 
Harish Gopinath et al.
72
 formulated and evaluated the captopril microencapsules – 
A sustained release approach. Microspheres and micropellets of captopril were prepared 
with different polymers (chitosan, ethyl cellulose, hydroxypropyl methyl cellulose and 
sodium alginate) by different techniques of microencapsulation (emulsion-phase 
separation, solvent-evaporation and ionotropic-gelation). The results revealed that all the 
formulations prepared, showed good drug incorporation efficiency and an extended 
release of the drug, thereby enhancing the duration of action. 
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Sahu et al.
73
 formulated and evaluated the captopril microspheres by ionic 
gelation technique. Captopril microspheres were prepared with a coat consisting  of 
alginate and polymer such as HPMC, Sodium alginate, Sodium Carboxymethyl cellulose, 
by Ionic cross linking technique using CaCl2.  From this study it is concluded that the 
drug polymer ratio and stirring speed were important for obtained desired spherical 
particles. The yield was found to be high in the formulations. The release rate of captopril 
from the microspheres was slow depending upon the amount and type of polymers used.    
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AIM OF THE WORK 
 To formulate and evaluate Floating Pulsatile tablet of Captopril providing 
chronomodulated therapy for  better treatment of Hypertension 
 To prepare the rapid release core tablets of Captopril using various 
superdisintegrants such as sodium starch glycolate, croscarmellose sodium, 
crospovidone by direct compression 
 Compression coating of optimized core tablets using hydrophilic polymers such 
as HPMC E5, HPMC K4M, HPMC K15M and Xanthan gum by direct 
compression 
 
OBJECTIVE 
 To provide drug release at the time when it is needed most. 
 To reduce dose related side effects. 
 To enhance the bioavailability of the drug. 
 
PLAN OF WORK  
The present study was designed and planned as follows:  
I. Compatibility studies  
 Physical compatibility study – at room temperature and accelerated 
condition (40º C ± 75 RH)   
 Chemical compatibility study – Fourier transform Infra-Red Spectroscopy      
(FT-IR) study (identification and compatibility of drug and excipients)  
II. Preparation of Standard curve for CAPTOPRIL  
III. Pre-formulation studies of drug and formulations  
IV. Formulation and Development of Rapid release core tablet of Captopril 
V. Evaluation of Rapid release core tablet of Captopril 
 Physical characteristics  
 Description  
 Uniformity of weight  
 Diameter and thickness  
 Hardness  
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 Friability  
 Drug content  
 Disintegration study 
 In-vitro release study   
VI. Formulation and Development of Floating Pulsatile release tablet of Captopril 
VII. Evaluation of Compression coated (FPRT) tablets  
 Physical characteristics  
 Description  
 Uniformity of weight  
 Diameter and thickness  
 Hardness  
 Friability  
 Drug content  
 In-vitro release study 
 In-vitro buoyancy studies 
 Swelling index determination 
 Release kinetics of optimized formulation 
 Stability study of optimized formulation as per ICH guidelines    
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4. 1. RATIONALE FOR SELECTION OF DRUG
60, 76
 
 CAPTOPRIL belongs to the class of ACE inhibitors, mainly used in the treatment 
of hypertension, congestive heart failure, nephropathy and myocardial infarction. 
 It has a shorter half life (<2hours) 
 It is unstable in lower part of GIT, well absorbed in stomach. 
 Bioavailability of 60-70%. Presence of food affects the absorption. 
 
4. 2. RATIONALE FOR SELECTION OF DOSAGE FORM
10, 13, 14
 
 Chronopharmacotherapy of diseases which show circadian rhythms in their 
pathophysiology. 
 Avoiding first pass metabolism. 
 For targeting the specific site e.g. Stomach. 
 For time programmed administration of drugs. 
 For drugs having short half life. 
 Improved bioavailability 
 Reduced side effects and dosage frequency, improved patient compliance 
 
4.3. RATIONALE FOR SELECTION OF HYPERTENSION
16
 
 Heart rate and blood pressure will be high at the time we wake up in the morning 
i.e. A.M and it will begin to decrease in the afternoon and it reaches to the minimum at 
midnight. But the blood pressure is comparatively high in case of hypertension patients 
upon awakening. This physiological condition is described as morning surge or A.M. 
surge. The systolic blood pressure rises up to 3mmHg/hour for 4-6 hours after getting up 
called post-awakening and the diastolic myocardial ischemia takes the lead as well in the 
morning 
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5.1. HYPERTENSION
75, 76, 77, 78
 
           Hypertension is defined as the condition in which the arteries have persistently 
elevated blood pressure. Arteries are the blood vessels that carry oxygenated blood from 
the heart to the body tissues.  
 
5.2. EPIDEMIOLOGY
77
             
Hypertension is one of the leading causes of the global burden of disease. 
Approximately 7.6 million deaths (13–15% of the total) and 92 million disability-
adjusted life years worldwide were attributable to high blood pressure in 2001. 
Hypertension doubles the risk of cardiovascular diseases, including coronary heart 
disease (CHD), congestive heart failure (CHF), ischemic and hemorrhagic stroke, renal 
failure, and peripheral arterial disease. It often associated with additional cardiovascular 
disease risk factors, and the risk of cardiovascular disease increases with the total burden 
of risk factors. Although antihypertensive therapy clearly reduces the risks of 
cardiovascular and renal disease, large segments of the hypertensive population are either 
untreated or inadequately treated.  
Both environmental and genetic factors may contribute to regional and racial 
variations in blood pressure and hypertension prevalence. Studies of societies undergoing 
"acculturation" and studies of migrants from a less to a more urbanized setting indicate a 
profound environmental contribution to blood pressure. Obesity and weight gain are 
strong, independent risk factors for hypertension. It has been estimated that 60% of 
hypertensive’s are >20% overweight. Among populations, hypertension prevalence is 
related to dietary NaCl intake, and the age-related increase in blood pressure may be 
augmented by a high NaCl intake. Low dietary intakes of calcium and potassium also 
may contribute to the risk of hypertension. Alcohol consumption, psychosocial stress, and 
low levels of physical activity also may contribute to hypertension. 
 
5.3. CLASSIFICATION
78
  
 Primary hypertension: It is also called essential or idiopathic hypertension, affects 
90-95% of hypertensive individuals. The causes include genetic and 
environmental factors.  
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 Secondary hypertension: It is caused by another medical condition or treatment. 
Their cause includes kidney problems, adrenal gland tumors, thyroid disease and 
narrowing of aorta.  
 Isolated systolic hypertension: In this, systolic pressure is above 140mm of Hg 
but diastolic pressure remains normal. 
 Malignant hypertension: It is a severe form of hypertension and death may occur 
within few months, if left untreated. 
 
Fig. 7: Etiology of hypertension 
Table 2: Criteria for diagnosis 
CATEGORY 
SYSTOLIC 
(mm/Hg) 
DIASTOLIC 
(mm/Hg) 
Normal 90-119 60-79 
High normal 
(Pre hypertension) 
120-139 80-89 
Stage I hypertension 140-159 90-99 
Stage II hypertension 160-179 100-109 
Stage III hypertension 
(emergency) 
≥ 180 ≥110 
Isolated systolic 
hypertension 
≥140 <90 
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5.4. RISK FACTORS 
FOR PRIMARY HYPERTENSION:  
 Family history     
 High intake of sodium and fat  
 Sedentary life style  
 Obesity, stress  
 Excessive alcohol consumption  
FOR SECONDARY HYPERTENSION:  
 Renal Artery disease  
 Mineral deficiencies(calcium, potassium, magnesium)  
 Brain tumor, quadriplegia, head injury  
 Thyroid, pituitary or parathyroid dysfunction. 
  
5.5. PATHOPHYSIOLOGY OF BP REGULATION
75, 76
   
The exact cause of hypertension is unknown. Arterial Blood Pressure is a product 
of cardiac output and peripheral resistance. Peripheral resistance is increased by factors 
that increase blood viscosity or reduce the lumen size of vessels 
.     
      
        Fig. 8: Pathology of hypertensive heart 
Mechanisms leading to hypertension are 
 Changes in the arteriolar blood causing increased peripheral vascular resistance. 
 Increased blood volume resulting from renal or hormonal dysfunction.  
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 Thickening of arteriolar caused by genetic factors leading to increased peripheral 
resistance.  
 Renin Angiotensin aldosterone system along with abnormalities in renal tubules 
also plays a part.  
 Increased circulatory blood volume and increased peripheral resistances are main 
pathophysiological mechanisms.  
1. Abnormal Na transport 
In many cases of hypertension, Na transport across the cell wall is abnormal, because the 
Na-K pump (Na
+
, K
+
-ATPase) is defective or inhibited or because permeability to Na
+
 is 
increased. The result is increased intracellular Na, which makes the cell more sensitive to 
sympathetic stimulation. Ca follows Na, so accumulation of intracellular Ca may be 
responsible for the increased sensitivity. Because Na
+
, K
+
-ATPase may 
pump norepinephrine back into sympathetic neurons (thus inactivating this 
neurotransmitter), inhibition of this mechanism could also enhance the effect 
of norepinephrine , increasing BP. Defects in Na transport may occur in normotensive 
children of hypertensive parents. 
2. Sympathetic nervous system 
Sympathetic stimulation increases BP, usually more in patients with prehypertension 
(systolic BP 120 to 139 mm Hg, diastolic BP 80 to 89 mm Hg) or hypertension (systolic 
BP ≥ 140 mm Hg, diastolic BP ≥ 90 mm Hg, or both) than in normotensive patients. 
Whether this hyperresponsiveness resides in the sympathetic nervous system or in the 
myocardium and vascular smooth muscle is unknown. A high resting pulse rate, which 
may result from increased sympathetic nervous activity, is a well-known predictor of 
hypertension. In some hypertensive patients, circulating plasma catecholamine levels 
during rest are higher than normal. 
3. Renin-angiotensin-aldosterone system 
This system helps regulate blood volume and therefore BP. Renin, an enzyme formed in 
the juxtaglomerular apparatus, catalyzes conversion of angiotensinogen to angiotensin I. 
This inactive product is cleaved by ACE, mainly in the lungs but also in the kidneys and 
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brain, to angiotensin II, a potent vasoconstrictor that also stimulates autonomic centers in 
the brain to increase sympathetic discharge and stimulates release of aldosterone and 
ADH. Aldosterone and ADH cause Na and water retention, elevating BP. Aldosterone 
also enhances K excretion; low plasma K (< 3.5 mEq/L) increases vasoconstriction 
through closure of K channels. Angiotensin III, present in the circulation, stimulates 
aldosterone release as actively as angiotensin II but has much less pressor activity. 
Because chymase enzymes also convert angiotensin I to angiotensin II, drugs that inhibit 
ACE do not fully suppress angiotensin II production. 
 
Fig. 9: Renin-Angiotensin-Aldosterone mechanism 
Renin secretion is controlled by at least 4 mechanisms:  
(1) A renal vascular receptor responds to changes in tension in the afferent arteriolar wall; 
(2) a macula densa receptor detects changes in the delivery rate or concentration of NaCl 
in the distal tubule;  
(3) circulating angiotensin has a negative feedback effect on renin secretion; and  
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(4) via the renal nerve, the sympathetic nervous system stimulates renin secretion 
mediated by β-receptors. 
4. Vasodilator deficiency 
Deficiency of a vasodilator (eg, bradykinin, nitric oxide) rather than excess of a 
vasoconstrictor (eg, angiotensin, norepinephrine ) may cause hypertension. If the kidneys 
do not produce adequate amounts of vasodilators (because of renal parenchymal disease 
or bilateral nephrectomy), BP can increase. Vasodilators and vasoconstrictors (mainly 
endothelin) are also produced in endothelial cells. Therefore, endothelial dysfunction 
greatly affects BP. 
5.6. SIGNS AND SYMPTOMS
78
  
 Headache, some quite severe  
 Dizziness  
 Fatigue  
 Irregular heart beat  
 Confusion  
 Vision problems  
 Chest pain   
 Nocturia  
 
5.7. DIAGNOSIS
77
 
 Multiple measurements of BP to confirm 
 Urinalysis and urinary albumin:creatinine ratio; if abnormal, consider renal 
ultrasonography 
 Blood tests: Fasting lipids, creatinine, K 
 Renal ultrasonography if creatinine increased 
 Evaluate for aldosteronism if K decreased 
 ECG: If left ventricular hypertrophy, consider echocardiography 
 Sometimes thyroid-stimulating hormone measurement 
 Evaluate for pheochromocytoma or a sleep disorder if BP elevation sudden and 
labile or severe 
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Hypertension is diagnosed and classified by sphygmomanometer. History, 
physical examination, and other tests help identify etiology and determine 
whether target organs are damaged. 
 
5.8. MANAGEMENT OF HYPERTENSION 
76, 78
 
LIFESTYLE MODIFICATIONS 
The first line of treatment for hypertension is lifestyle changes, including dietary 
changes, physical exercise, and weight loss. These have all been shown to significantly 
reduce blood pressure in people with hypertension. Their potential effectiveness is similar 
to and at times exceeds a single medication.  
 Dietary changes shown to reduce blood pressure include diets with low 
sodium, the DASH diet, vegetarian diets and high potassium diets. 
Physical exercise regimens which are shown to reduce blood pressure 
include isometric resistance exercise, aerobic exercise, resistance exercise, and device-
guided breathing. 
Stress reduction techniques such as biofeedback or transcendental meditation may 
be considered as an add-on to other treatments to reduce hypertension, but do not have 
evidence for preventing cardiovascular disease on their own. 
 
MEDICATIONS 
 Diuretics  
 Angiotensin converting enzymes (ACE) inhibitors  
 Angiotension receptor blockers 
 Alpha adrenergic receptor blockers  
 Beta adrenergic receptor blockers  
 Calcium channel blockers  
 Central adrenergic inhibitors  
 Vasodilators 
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CAPTOPRIL
76, 79, 80
 
PHYSIOCHEMICAL PROPERTIES 
Structure: 
   
Molecular formula  : C9H15NO3S 
Molecular weight  : 217.285 
Chemical Name                     : (2S)-1-[(2S)-2-methyl-3-sulfanylpropanoyl] pyrrolidie-2- 
carboxylic acid 
CAS Number   : 62571-86-2 
Category      : Angiotensin – Converting Enzyme Inhibitors 
       Antihypertensive agents 
Description : A white to off-white, crystalline powder; odour, 
characteristic, sulphide-like. 
Solubility   : freely soluble 
Storage      : Store protected from moisture 
Melting Point   : 104°C to 110°C 
 
INDICATION
76 
 For the treatment of essential or renovascular hypertension (usually administered 
with other drugs, particularly thiazide diuretics).  
 It is used to treat congestive heart failure in combination with other drugs (e.g. 
cardiac glycosides, diuretics, β-adrenergic blockers).  
 It improves survival in patients with left ventricular dysfunction following 
myocardial infarction.  
 It can be used to treat nephropathy, including diabetic nephropathy. 
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DOSE: Initially, 12.5 to 50mg twice daily; usual maintenance dose, 25mg twice daily; 
maximum, 50mg twice daily 
 
PHARMACOKINETICS
76
 
 Absorption: 60-75% in fasting individuals; food decreases absorption by 25-40% 
 Protein Binding: 25-30% bound to plasma proteins, primarily albumin 
 Metabolism: Hepatic. Major metabolites are captopril-cysteine disulfide and the 
disulfide dimer of captopril. Metabolites may undergo reversible interconversion. 
 Elimination T1/2: 2 Hours  
 Excretion: Renal 
 
PHARMACODYNAMICS
80
 
Captopril, an ACE inhibitor, antagonizes the effect of the RAAS. The RAAS is a 
homeostatic mechanism for regulating hemodynamics, water and electrolyte balance. 
During sympathetic stimulation or when renal blood pressure or blood flow is reduced, 
renin is released from the granular cells of the juxtaglomerular apparatus in the kidneys. 
In the blood stream, renin cleaves circulating angiotensinogen to ATI, which is 
subsequently cleaved to ATII by ACE. ATII increases blood pressure using a number of 
mechanisms. First, it stimulates the secretion of aldosterone from the adrenal cortex. 
Aldosterone travels to the distal convoluted tubule (DCT) and collecting tubule of 
nephrons where it increases sodium and water reabsorption by increasing the number of 
sodium channels and sodium-potassium ATPases on cell membranes. Second, ATII 
stimulates the secretion of vasopressin (also known as antidiuretic hormone or ADH) 
from the posterior pituitary gland. ADH stimulates further water reabsorption from the 
kidneys via insertion of aquaporin-2 channels on the apical surface of cells of the DCT 
and collecting tubules. Third, ATII increases blood pressure through direct arterial 
vasoconstriction. Stimulation of the Type 1 ATII receptor on vascular smooth muscle 
cells leads to a cascade of events resulting in myocyte contraction and vasoconstriction. 
In addition to these major effects, ATII induces the thirst response via stimulation of 
hypothalamic neurons. ACE inhibitors inhibit the rapid conversion of ATI to ATII and 
antagonize RAAS-induced increases in blood pressure. ACE (also known as kininase II) 
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is also involved in the enzymatic deactivation of bradykinin, a vasodilator. Inhibiting the 
deactivation of bradykinin increases bradykinin levels and may sustain its effects by 
causing increased vasodilation and decreased blood pressure. 
 
MECHANISM OF ACTION
80
  
There are two isoforms of ACE: the somatic isoform, which exists as a 
glycoprotein comprised of a single polypeptide chain of 1277; and the testicular isoform, 
which has a lower molecular mass and is thought to play a role in sperm maturation and 
binding of sperm to the oviduct epithelium. Somatic ACE has two functionally active 
domains, N and C, which arise from tandem gene duplication. Although the two domains 
have high sequence similarity, they play distinct physiological roles. The C-domain is 
predominantly involved in blood pressure regulation while the N-domain plays a role in 
hematopoietic stem cell differentiation and proliferation. ACE inhibitors bind to and 
inhibit the activity of both domains, but have much greater affinity for and inhibitory 
activity against the C-domain. Captopril, one of the few ACE inhibitors that are not a 
prodrug, competes with ATI for binding to ACE and inhibits and enzymatic proteolysis 
of ATI to ATII. Decreasing ATII levels in the body decreases blood pressure by 
inhibiting the pressor effects of ATII as described in the Pharmacology section above. 
Captopril also causes an increase in plasma renin activity likely due to a loss of feedback 
inhibition mediated by ATII on the release of renin and/or stimulation of reflex 
mechanisms via baroreceptors. Captopril’s affinity for ACE is approximately 30,000 
times greater than that of ATI. 
 
TOXICITY
76, 80
 
 Symptoms of overdose include emesis and decreased blood pressure.  
 Side effects include dose-dependent rash (usually maculopapular), taste 
alterations, hypotension, gastric irritation, cough, and angioedema. 
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7. PHARMACEUTICAL EXCIPIENTS
1, 2 
 
Excipients are substances other than the pharmacologically active drug or 
prodrugs, which are included in the manufacturing process or contained in the 
pharmaceutical finished product or dosage form. 
Excipients play a wide variety of functional role in pharmaceuticals dosage forms 
including; 
 Modifies the solubility and bioavailability of active pharmaceutical ingredients 
(APIs). 
 Increasing the stability of active ingredients the dosage forms. 
 Maintaining the pH and/or osmolarity of liquid formulations. 
 Helping active ingredients maintained preferred polymorphic Forms or 
conformation 
 Modulating immunogenic responses of active ingredients (e.g.adjuvants). 
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7.1. HYDROXY PROPYL METHYL CELLULOSE
82 
1. Non-proprietary Name:  
BP: Hypromellose, JP: Hypromellose PhEur: Hypromellose USP: Hypromellose 
2. Synonyms:   
Benecel MHPC; E464; hydroxyl propyl methyl cellulose; HPMC hypromellosum; 
methocel; methyl cellulose propylene glycol ether; methyl hydroxyl propyl 
cellulose; metolose; MHPC; Pharmacoat; Tylophor; Tylose  
3. Chemical Name:  
Cellulose hydroxyl propyl methyl ether   
4. Molecular weight:   
Molecular weight approximately 10000-1500000 
5. Functional category:  
Bio adhesive material, coating agent, controlled release agent, emulsifying agent, 
film forming agent, extended-release agent, suspending agent, sustained release 
agent, tablet binder. 
6. Description:  
Hypromellose is an odourless and tasteless, white or creamy – white fibrous or 
granular powder.  
7. Solubility :  
Soluble in cold water, forming a viscous colloidal solution; practically insoluble 
in hot water, chloroform, ethanol (95%) and ether 
8. Applications: 
   HPMC is widely used in oral, ophthalmic, nasal and topical pharmaceutical 
formulations. It is used as tablet binder in film-coating and as a matrix for extended 
release tablet formulations, concentrations between 2-5% used as binder in either wet 
or dry granulation processes. High viscosity grades may be used to retard the release 
of drugs from a matrix at levels of 10-80%w/w in tablets and capsules. Hypromellose 
is also used in liquid oral dosage forms as a suspending and/or thickening agent at 
concentrations ranging from 0.25-5.0% 
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7.2. XANTHAN GUM
82
 
1. Non-proprietary names:  
BP: Xanthan gum, PhEur: Xanthani gummi, USP-NF: Xanthan gum  
2. Synonyms:  
Corn sugar gum; E415; Keltrol; polysaccharide B-1459, Rhodigel, Vansan NF, 
Xantural. 
3. Chemical name:  
Xanthan gum  
4. Empirical formula and Molecular weight:  
(C35H49O29)n. Xanthan gum as a high molecular weight polysaccharide gum. It 
contains D-glucose and D-mannose as a dominant hexose units, along with D- 
glucuronic acid and is prepared as the sodium, potassium or calcium salt.  
5. Structural formula:  
Each xanthan gum repeat units contains five sugar residues: two glucose, two 
mannose and one glucuronic acid. The polymer backbone consist of four b-D-glucose 
units linked the 1 and 4 positions and is therefore identical in structure to cellulose   
6. Functional category:  
Stabilizing agent; viscosity increasing agent; suspending agent.  
7.   Description:  
Xanthan gum occurs as a cream or white colored odourless, free flowing, fine 
powder  
8. Applications:  
Xanthan gum is widely used in oral and topical formulation cosmetics and food as 
a stabilizing agent. It is also used as emulsifying agent and thickening agent, it is non- 
toxic, compatible with most other pharmaceutical ingredients and has good stability and 
viscosity properties over wide pH and temperature range, it is also used as a matrix 
former in sustained release tablets, and it increases the retention time of the ophthalmic 
solutions in eye and as Bioadhesive polymer.   
9. Stability:  
Xanthan gum is a stable material. Aqueous solutions are stable over a wide pH 
range (pH 3-12), the stability at pH 4- 10 and temperature at 10-60 is maximum. 
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7.3. CROS CARMELLOSE SODIUM
82
 
1. Non-proprietary Name:  
BP: Croscarmellose sodium, PhEur: Carmellosum natricum conexum, USPNF: 
Croscarmellose sodium  
2. Synonyms:  
Ac-Di-Sol; croslinked carboxy methyl cellulose sodium; Explocel; modified 
cellulose gum; Nymcel ZSX; Pharmacel XL; Primellose; Solutab; Vivasol  
3. Chemical Name:   
Cellulose, carboxymethyl ether, sodium salt,cross-linked   
4. Empirical formula and Molecular Weight:  
C12H10Ca3O14. 4H2O; 570.49  
5. Functional Category:  
Tablet and capsule disintegrant  
6. Description:  
Croscarmellose sodium occurs as an odourless, white or grayish white powder.  
7. Incompatibilities:  
The efficacy of disintegrants, such as croscarmellose sodium, may be slightly 
reduced in tablet formulations prepared by either the wet-granulation or direct-
compression process that contain hygroscopic excipients such as sorbitol.  
8. Applications:  
Croscarmellose sodium may be used in both direct compression and wet 
granulation processes. When used in wet granulation’s, the croscarmellose sodium should 
be added in both wet and dry stages of the process (intra and extra granularly) so that the 
wicking and swelling ability of the disintegrant is best utilized. Croscarmellose sodium at 
concentrations up to 5% w/w may be used as tablet disintegrant, although normally 2% 
w/w is used in tablets prepared by direct compression and 3% w/w in tablets prepared by 
wet granulation process. 
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7.4. SODIUM STARCH GLYCOLATE
82
 
1. Non-proprietary Name:  
BP: Sodium Starch Glycolate, PhEur: Sodium Starch Glycolate  
2. Synonyms:  
Carboxymethyl starch, Sodium salt, Carboxymethyl amylum natricum; 
Explosol,glycols, primojel, tablo; vivastar p.  
3. Chemical Name:   
Sodium Carboxymethyl Starch  
4. Functional Category:  
Tablet and Capsule disintegrant  
5. Description:  
Sodium starch glycolate is a white or almost white free-flowing hygroscopic 
powder  
6. Solubility:  
Practically insoluble in methylene chloride. It gives a translucent suspension in 
water  
7. Applications:   
It is widely used in oral pharmaceuticals as a disintegrant in capsule and tablet 
formulations. It is commonly used in tablet prepared by direct compression or wet 
granulation process. The usual concentration employed in formulation is between 2% and 
8%, with the optimum concentration of about 4%. Disintegration occurs by rapid uptake 
of water and enormous swelling. Increasing the tablet compression pressure also appears 
to have no effect on disintegration time. 
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7.5. CROS POVIDONE
82
 
1. Non-proprietary Name:  
BP: Crospovidone, PhEur: Crospovidonum, USPNF: Crospovidone   
2. Synonyms:  
Cross-linked povidone; E1202; Kollidon CL; Kollidon CL-M; Polyplasdone XL; 
Polyplasdone XL-10; Polyvinylpolypyrrolidone; PVPP; 1-vinyl-2-pyrrolidinone 
homopolymer  
3. Chemical Name:   
1-Ethenyl-2-pyrrolidinone homopolymer  
4. Empirical formula and Molecular Weight:  
(C6H9NO)n > 1000000  
5. Functional Category:  
Tablet disintegrant  
6. Description:  
Crospovidone is a creamy white, finely divided, free flowing, practically tasteless, 
odourless or nearly odourless, hygroscopic powder.  
7. Solubility:  
Soluble in cold water, forming a viscous colloidal solution; practically insoluble 
in hot water, chloroform, ethanol (95%) and ether. 
8. Incompatibilities:  
Crospovidone is compatible with most organic and inorganic pharmaceutical 
ingredients. When exposed to a high water level, crospovidone may form molecular 
adducts with some materials  
9. Applications:  
Crospovidone is a water insoluble tablet disintegrant and dissolution agent used at 
2-5% concentration I tablets prepared by direct compression or wet and dry granulation 
methods. It rapidly exhibits high capillary activity and pronounced hydration capacity, 
with little tendency to form gels. Crospovidone can also be used as a solubility enhancer. 
With the technique of co-evaporation, crospovidone can be used to enhance the solubility 
of poorly soluble drugs.   
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7.6. SODIUM BICARBONATE
82
 
1. Non-proprietary name:  
BP: Sodium bicarbonate, JP: Sodium bicarbonate, PhEur: Natrii hydrogeno 
carbonas, USP: Sodium bicarbonate  
2. Synonyms:  
Baking soda; E500; Effer –soda; monosodium carbonate; Sal de vichy; Sodium 
acid carbonate; sodium hydrogen carbonate.  
3. Chemical Name:  
Carbonic acid monosodium salt   
4. Empirical Formula:   
NaHCO3 84.01  
5. Functional Category:  
Alkalizing and therapeutic agents                                    
6. Description:  
Sodium bicarbonate occurs as an odourless, white, crystalline powder with saline, 
slightly alkaline taste. The crystal structure is monoclinic prisms.  
7. Incompatibilities:  
Reacts with acids, acidic salts and alkaloidal salts  
8. Applications:  
Sodium bicarbonate is used as a source of CO2 in the formulation or technology 
effervescent tablets and granules. In effervescent tablet and granules, sodium bicarbonate 
is usually formulated with citric acid or tartaric acid; tablets prepared with sodium 
bicarbonate alone since the gastric fluid is sufficient to produce the effervescences; it is 
also used in tablet formulations to buffer the drug molecules that are weak acids, thereby 
increasing the rate of dissolution and reducing gastric irritation. Recently it is used as a 
gas generating agent in floating systems and alginate raft systems.    
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7.7. MICROCRYSTALLINE CELLULOSE
82
 
1. Non-proprietary Name:  
BP: Microcrystalline Cellulose, USP-NF: Microcrystalline Cellulose  
2. Synonyms:  
Avicel PH; Cellulose gel, Crystalline cellulose  
3. Chemical Name:   
Cellulose  
4. Empirical Formula:  
(C6H10O5)n ; where n = 220  
5. Functional Category:  
Tablet and capsule diluents, Adsorbent, tablet disintegrant, suspending agent  
6. Description:  
Microcrystalline cellulose is purified, partially depolymerized cellulose that 
occurs as a white odourless, tasteless, crystalline powder composed of porous particles. It 
is commercially available in different particles sizes and moisture grades that have 
different properties and applications  
7. Solubility:  
Slightly soluble in 5% w/v sodium hydroxide solution; practically insoluble in 
water, dilute acids and most organic solvents  
8. Incompatibilities:   
Microcrystalline cellulose is incompatible with strong oxidizing agents  
9. Applications:  
Microcrystalline cellulose is widely used in pharmaceuticals, primarily as a 
binder/diluent in oral tablet and capsule formulations where it is used in both wet- 
granulation and direct-compression processes. In addition to its use as binder/diluents, 
microcrystalline cellulose also has some lubricant and disintegrant properties that make it 
useful in tableting 
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7.8. LACTOSE
82
 
1. Non-proprietary Names:    
BP: Lactose, PhEur: Lactose Monohydrate, USP-NF: Lactose monohydrate 
2. Synonyms:             
CapsuLac, GranuLac, Lactochem; lactosum monohydricum Monohydrate; 
Pharmatose, PrismaLac; SacheLac; SorboLac; SpheroLac; SuperTab 30GR; Tablettose.  
3. Chemical Name:               
O-b-D-Galactopyranosyl - (1-4)-a-D-glucopyranose monohydrate  
4. Empirical Formula:  
C12H22O11. H2O  
5. Molecular Weight:  
360.31  
6. Functional Category:  
Dry powder inhaler carrier; lyophilisation aid; tablet binder; tablet and capsule 
diluent; tablet and capsule filler.  
7. Description:  
The stable crystalline forms of lactose are a-lactose monohydrate, b-lactose 
anhydrous and stable α-lactose anhydrous. Lactose occurs as white to off-white 
crystalline particles or powder. Lactose is odourless and slightly sweet-tasting; α-lactose 
is approximately 20% as sweet as sucrose, while β-lactose is 40% as sweet.  
8. Solubility:  
Practically insoluble in chloroform, ethanol, ether; soluble in water.  
9. Applications:  
Lactose is widely used as a filler and diluent in tablets and capsules. Lactose is 
also used as a diluent in dry-powder inhalation. Lactose is also used in the manufacture of 
dry powder formulations for use as aqueous film-coating solutions or suspensions. 
Lactose is also used in combination with sucrose (approximately 1: 3) to prepare sugar- 
coating solutions.   
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7.9. MAGNESIUM STEARATE
82
 
1. Non-proprietary Name:  
BP: Magnesium Stearate, JP: Magnesium Stearate, PhEur: Magnesium 
Stearate,USP-NF: Magnesium Stearate  
2. Synonyms:  
Dibasic Magnesium stearate, Magnesium distearate; Magnesia stearas, 
Magnesium octadeconoate; Octadecanoic acid, Magnesium salt; Synpro 90  
3. Chemical Name:   
Octadecanoic acid, Magnesium salt  
4. Empirical Formula:  
C36H70MgO4  
5. Molecular weight:  
591.24  
6. Functional Category:  
Tablet and Capsule lubricant  
7. Description:   
Magnesium stearate is a very fine, light white, impalpable powder of low bulk 
density, having a faint odour of stearic acid and a characteristic taste. The powder is 
greasy to the touch and readily adheres to the skin.  
8. Incompatibility:  
Incompatible with strong acids, alkalis and iron salts  
9. Applications:  
It is primarily used as lubricant in capsule and tablet manufacture at 
concentrations between 0.25% and 5% w/w. It is hydrophobic and may retard the 
dissolution of a drug from solid dosage form. The lowest possible concentration is 
therefore used in such formulations   
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7.10. TALC
82 
1. Non-proprietary Name:  
BP: Purified Talc, JP: Talc, PhEur: Talc, USP-NF: Talc  
2. Synonyms:  
Magnesium hydrogen metasillicate, Magsil Osmanthus, Magsil Star  
3. Chemical Name:   
Talc  
4. Empirical Formula:  
Mg6 (Si2O5)4(OH)4  
5. Functional Category:  
Anticaking agent, glidant, tablet and capsule diluents, tablet and capsule lubricant  
6. Description:  
Talc is a very fine, white to greyish-white, odourless, impalpable, unctuous, 
crystalline powder  
7. Solubility:  
Practically insoluble in dilute acids and alkalis, organic solvents and water   
8. Incompatibility:  
Incompatible with quaternary ammonium compounds  
9. Applications:  
Talc was once widely used in oral solid dosage formulations as a lubricant and 
diluents. It is widely used as a dissolution retardant in the development of controlled 
release products. Talc is additionally used to clarify liquids and is also used in cosmetics 
and food products, mainly for its lubricant properties.    
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7.11. ERYTHROSIN
82
 
1. Non-proprietary Name:  
Erythrosine natrium  
2. Synonyms:  
Erythrosine B; Erythrosine B; Acid Red 51; C.I. 45430; FD & C Red No.3; E127; 
2',4',5',7'–Tetraiodo-3',6'-dihydroxy-spiro[3H-isobenzofuran-1,9'-xanthen]-3-one 
disodium salt; Tetraiodofluorescien sodium salt; Calcoid Erthrosine N; 2',4',5',7' – 
Tetraiodo-3',6'-dihydroxyxanthen-9-spiro-1'-3H-isobenzofuran-3'-one disodium salt; 
2',4',5',7' –Tetraiodofluorescein disodium salt; C.I.Food Red 14; Aizen Erythrosine; 
Tetraiodifluorescein disodium salt; Spiro[isobenzofuran-1(3H),9'-[9H]xanthen]-3-one, 
3',6'-dihydroxy-2',4',5',7'-tetraiodo disodium salt  
3. Chemical Name:  
 2-(6-Hydroxy-2,4,5,7-tetraiodo-3-oxo-xanthen-9-yl) benzoic acid  
4. Empirical Formula:  
C20H6I4Na2O5  
5. Molecular Weight:  
879.86 g/mol  
6. Melting Point:  
303º C  
7. Functional Category:  
It is a cherry pink synthetic colourant  
8. Description:  
Maroon colour powder and hygroscopic  
9. Application:  
Erythrosine B is an iodo derivative of fluoresin with distinctly bluish shade 
whereas eosin is a bromine derivatives of fluoresin. It is used in colouring cosmetics and 
food. It is used in colouring cosmetics and food. It is used as a plasma stain for nerve 
cells and staining bacteria in soil. It is used as a phosphorescent triplet probe to detect 
rotational diffusion of membrane proteins   
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  Table 3: List of materials and their application in formulation 
S.No. Name of the material 
Manufacturer / 
Supplier 
Use in 
formulation 
1 Captopril 
Unicure (India) 
Pvt. Ltd., 
Active 
Pharmaceutical 
Ingredient 
2 
Sodium Starch 
Glycolate 
Kniss Laboratories 
Super 
Disintegrant 
3 Cros Povidone Kniss Laboratories 
Super 
Disintegrant 
4 
Cros Carmellose 
Sodium 
Kniss Laboratories 
Super 
Disintegrant 
5 Xanthan gum Kniss Laboratories 
Hydrophilic 
polymer 
6 HPMC K15M 
Sai Mirra Innopharm 
Pvt. Ltd., 
Hydrophilic 
polymer 
7 HPMC E15 
Colorcon Asia Pvt. 
Ltd., 
Hydrophilic 
polymer 
8 HPMC K4M Kniss Laboratories 
Hydrophilic 
polymer 
9 Sodium bicarbonate 
Indian Research 
products 
Gas generating 
agent 
10 
Microcrystalline 
Cellulose 
Pharma French Ltd Diluent 
11 Lactose Kniss Laboratories Diluent 
12 Magnesium Stearate Kniss Laboratories Lubricant 
13 Talc Kniss Laboratories Glidant 
14 Erythrosine 
Kwality 
pharmaceuticals 
Colorant 
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Table 4: List of Equipments used 
S.No. Equipments / Instruments Manufacturer / Supplier 
1 Electronic weighing balance Asha scientific company, Mumbai 
2 Hot air oven MC Dalal, Chennai 
3 10 station compression machine Rimek India 
4 Vernier caliper Mitutoya, Japan 
5 Monsanto Hardness tester Standard steel, India 
6 Friabilator Electrolab, India 
7 pH Meter MC Dalal, Chennai 
8 Dissolution test apparatus Campbell, India 
9 UV-Visible Spectrophotometer Schimadzu, India 
10 
Fourier Transform 
Infrared Spectrophotometer Schimadzu, India 
11 Disintegration Apparatus Electrolab, India  
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PREFORMUALTION STUDIES 
The Preformulation studies are conducted to establish the physicochemical 
characteristics of the drug and its compatibility with the various excipients utilized in the 
formulation. The Preformulation studies are necessary to formulate the drug into stable, 
safe and effective dosage form. 
 
DRUG-EXCIPIENT COMPATIBILITY STUDY
83
 
The Drug and the Excipients selected for the formulation were evaluated for 
physical and chemical compatibility studies. 
Physical Compatibility study 
The physical compatibility studies were conducted to provide valuable 
information to the formulator in selecting the appropriate excipients for the formulation. 
It was done by mixing the drug and excipients and kept at room temperature and at 40° C 
and 75 % RH. Any colour change of the physical mixture was observed visually. 
 
Chemical Compatibility study 
Infrared spectroscopy can be used to identify a compound and also to investigate 
the composition of the mixture. Pure drug and Drug-Excipient mixtures were subjected to 
FT-IR to investigate the Drug-Excipient interactions. The IR spectra of the test samples 
were obtained by Pressed Pellet Technique using Potassium bromide. 
 
Potassium bromide pellet method 
A small amount of finely ground solid sample was intimately mixed with about 
100 times of its weight of powdered Potassium bromide. The finely ground mixture was 
then passed under high pressure in a press (at least 25,000 psig) to form a small pellet 
(about 1-2 mm thick and 1 cm in diameter). The resulting pellet was placed in the sample 
cell and the spectra were recorded. 
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PREPARATION OF BUFFER SOLUTION 
Preparation of 0.1N Hydrochloric acid (pH 1.2)
84
 
 8.5 ml of conc. Hydrochloric acid was dissolved in few ml of distilled water and 
volume made up to 1000 ml with distilled water. 
 
CALIBRATION CURVE
59, 73
 
 100 mg of Captopril was dissolved in a small amount of 0.1N Hydrochloric acid 
and made up to 100 ml with 0.1N Hydrochloric Acid in a standard flask. 10 ml of the 
solution was pipetted out into a standard flask and made up to 100 ml using 0.1N 
Hydrochloric Acid. 2 ml, 4 ml, 6 ml, 8 ml and 10 ml of the solution were pipetted into 
separate standard flasks and made up to 100 ml using 0.1N Hydrochloric Acid. The 
absorbance of the resulting solutions was measured at 212 nm using UV 
Spectrophotometer. Calibration curve was plotted using Concentration in x-axis and 
Absorbance in y-axis. 
 
PRECOMPRESSION STUDIES
85
 
The flow properties of powders are critical for an efficient tableting operation. A 
good flow of the powder or granulation to be compressed is necessary to assure efficient 
mixing and acceptable weight uniformity for the compressed tablets. The flow property 
measurements include bulk density, tapped density, angle of repose, compressibility 
index and Hausner’s ratio. The flow property measurements of drugs and blends are 
determined to select the type of granulation to be carried out in the formulation. 
 
PRECOMPRESSION STUDIES OF DRUG AND POWDER BLENDS
84, 85
 
1. Bulk density (ρb) 
59, 86
 
It is the ratio of total mass of powder to the bulk volume of powder. It was 
measured by pouring the weighed powder into a measuring cylinder and it was slightly 
shaken to break any agglomerates formed. The volume occupied by the powder was 
measured which gave bulk volume.  
Bulk density of the powder was calculated using the formula mentioned below. It 
is expressed in g/ml. 
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    ρb = M/Vb  
Where, M and Vb are mass of powder and bulk volume of the powder 
respectively.  
 
2. Tapped density (ρt) 
59, 86 
It is the ratio of weight of the powder to the tapped volume of powder. An 
accurately weighed powder was introduced into a measuring cylinder with the aid of a 
funnel. The measuring cylinder was tapped until no further change in volume was noted 
which gave the tapped volume. 
Tapped density of the powder was calculated using the formula mentioned below. 
It is expressed in g/ml. 
    ρt = M/Vt 
 Where, M and Vt are mass of powder and tapped volume of the powder 
respectively. 
 
3. Angle of repose (θ) 20, 59 
 It is defined as the maximum angle possible between the surface of a pile of 
powder and the horizontal plane. It was determined by the funnel method. The powder 
mixture was allowed to flow through the funnel freely onto the surface. The diameter of 
the powder cone was measured and angle of repose was calculated using the formula, 
Angle of Repose (θ) = tan-1 (h/r) 
 Where, h = Height of the pile of powder (in cm) 
 r = Radius of pile of powder (in cm) 
 
4. Compressibility Index (Carr’s Index) 20, 59 
 Compressibility index is the measure of flow property of a powder. It is measured 
for determining the relative importance of interparticulate interactions. It is expressed in 
percentage and calculated by the formula,  
Compressibility Index = TD – BD x 100 
                     TD 
 Where, TD is the tapped density and BD is the bulk density 
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5. Hausner’s Ratio 20, 59 
 Hausner’s ratio is an indirect index of ease of powder flow. Hausner’s ratio is the 
measure of propensity to be compressed and also Interparticulate interactions / 
Interparticulate friction. It was calculated by the following formula, 
    HR = ρt / ρb 
 Where, ρt and ρb are tapped density and bulk density respectively 
 
Table 5: Precompression Parameters
85
 
Flow Property 
Angle of Repose 
(in degrees) 
Compressibility 
Index (%) 
Hausner’s Ratio 
Excellent 25 – 30 < 10 1.00 - 1.11 
Good 31 – 35 11 – 15 1.12 - 1.18 
Fair 36 – 40 16 – 20 1.19 - 1.25 
Passable 41 – 45 21 – 25 1.26 - 1.34 
Poor 46 – 55 26 – 31 1.35 - 1.45 
Very Poor 56 – 65 32 – 37 1.46 - 1.59 
Very very Poor > 65 > 38 > 1.60 
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FORMULATION DEVELOPMENT 
Formulation of Rapid Release core tablets (RRCT) of Captopril 
22, 23, 24 
The inner core tablets of captopril were prepared by direct compression method. 
Different concentrations of various superdisintegrant such as sodium starch glycolate, 
croscarmellose sodium and crospovidone were used. The powder mixtures of captopril, 
superdisintegrant, microcrystalline cellulose, lactose were dry blended for 20 minutes, 
followed by addition of magnesium stearate. The mixtures were further blended for 10 
minutes. 100 mg of the resultant powder blend was compressed using 10 station tablet 
compression machine. 
 
Table 6: Formulation of rapid release core tablets 
S.No. Ingredients F1 F2 F3 F4 F5 F6 F7 F8 F9 
1. CAPTOPRIL 25 25 25 25 25 25 25 25 25 
2. 
Croscarmellose 
Sodium 
1 1.5 2 - - - - - - 
3. Crospovidone - - - 2 3.5 5 - - - 
4. 
Sodium starch 
glycolate 
- - - - - - 2 3 4 
5. 
Microcrystalline 
cellulose 
25 25 25 25 25 25 25 25 25 
6. Lactose 46 45.5 45 45 43.5 42 45 44 43 
7. Magnesium 
stearate 
3 3 3 3 3 3 3 3 3 
Average weight of each tablet = 100mg 
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Fig. 10: Flowchart for formulation of rapid release captopril tablet 
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Formulation of Captopril floating pulsatile release tablet (FPRT) 
22, 24, 27, 28 
 Floating pulsatile release tablets were prepared by press-coated method using 
HPMC E15, HPMC K4M, HPMC K15M, Xanthan gum (polymers) and sodium 
bicarbonate (gas generating agent). The compression coated tablets were prepared by first 
filling one half of the coating powder in the 10mm die cavity, then centrally positioning 
the tablet core on the powder bed, followed by filling the remaining half of the coating 
powder on top and followed by direct compression. 
 
Table 7:  Formulation of Floating pulsatile release tablets 
S. No Ingredients FP1 FP2 FP3 FP4 FP5 FP6 FP7 FP8 
1. 
Optimized 
core tablet 
100 100 100 100 100 100 100 100 
2. HPMC E15 150 - - - 200 250 200 200 
3. HPMC K15M - 150 - - - - 25 - 
4. HPMC K4M - - 150 - - - - 50 
5. Xanthan gum - - - 150 - - - - 
6. 
Sodium 
bicarbonate 
50 50 50 50 50 50 50 50 
7. Lactose 180 180 180 180 130 80 105 80 
8. 
Magnesium 
stearate 
10 10 10 10 10 10 10 10 
9. Talc 10 10 10 10 10 10 10 10 
Average weight of each tablet = 500mg 
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Fig. 11: Flowchart for formulation of captopril floating pulsatile tablet 
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POST COMPRESSION STUDIES
85 
PHYSICAL PARAMETERS
22, 26, 59 
General appearance 
The general appearance of the tablets from each formulation batch was observed. 
The general appearance parameters, shape and colour were evaluated visually.  
Uniformity of Weight 
Twenty tablets were randomly selected and weighed individually on an electronic 
weighing balance. The average weight was calculated. The percentage deviation of 
tablets was calculated and compared with standard specifications. 
Table 8: Uniformity of weight 
S No. Average weight of Tablet % Deviation 
1 80 mg or less 10 
2 80 to 250 mg 7.5 
3 More than 250 mg 5 
 
Thickness and diameter  
The thickness and diameter was measured to determine the uniformity of size and 
shape. Thickness and diameter of the tablets were measured using Vernier caliper. 
Hardness  
Hardness is defined as the force required for breaking a tablet at diametric 
compression test and it is termed as “Tablet Crushing strength”. Hardness of the prepared 
formulations was determined using Monsanto Hardness Tester. It was expressed in 
kg/cm
2
.  
Friability  
Friability of the prepared formulations was determined using Rochelle Friabilator. 
Pre-weighed sample of Tablets was placed in the Friability tester, which was then 
operated for 100 revolutions, Tablets were de-dusted and re-weighed. The Friability of 
the Tablets was calculated using the formula, 
 
% Friability = (Initial weight of the tablets – Final weight of the tablet) X100 
Initial weight of the tablets 
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Disintegration test for Captopril Core Tablets
59 
Tablet disintegration was carried out by placing one tablet in each tube of the 
basket and top portion of the each tube was closed with disc and run the apparatus 
containing 0.1N Hydrochloric acid (pH 1.2) [SGF (simulated gastric fluid)] maintained at 
37 °C as the immersion liquid. The assembly was raised and lowered for 30 cycles per 
minute. The time taken for the complete disintegration of the tablet with no palpable 
mass remaining in the apparatus was measured and recorded. The experiment was carried 
out in triplicate 
 
DRUG CONTENT 
I. For Rapid Release Core Tablets (RRCT) 
59 
 Five tablets were selected randomly, weighed and finely ground. An accurately 
weighed quantity of powder equivalent to 25mg of Captopril was transferred to a 100 ml 
standard flask and dissolved in few ml of 0.1N HCl and the volume was made up to the 
mark with 0.1N HCl. The solution was filtered and 10ml portion of the filtrate was 
further diluted with 0.1N HCl in a 100ml standard flask. The absorbance of the resulting 
solution was measured at 212nm taking 0.1 N HCl as blank using UV-Visible 
Spectrophotometer. The concentration was obtained from the calibration graph. 
 
II. For Floating Pulsatile Release Tablets (FPRT)
 24, 27 
 Five tablets were selected randomly, weighed and finely ground. An accurately 
weighed quantity of powder equivalent to 25mg of Captopril was transferred to a 100 ml 
standard flask and dissolved in few ml of 0.1N HCl and the volume was made up to the 
mark with 0.1N HCl. The solution was filtered and 10ml portion of the filtrate was 
further diluted with 0.1N HCl in a 100ml standard flask. The absorbance of the resulting 
solution was measured at 212nm taking 0.1 N HCl as blank using UV-Visible 
Spectrophotometer. The concentration was obtained from the calibration graph. 
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IN-VITRO STUDIES 
I. IN-VITRO DISSOLUTION STUDIES 
   For RRCT
22, 59
 
 The release of Captopril core tablet was determined using USP Type II (paddle 
type) apparatus. The dissolution test was performed using 900ml of 0.1N HCl (pH 1.2), at 
37°C ± 0.5°C. The paddle was rotated at the speed of 50 rpm. A sample (5ml) of the 
solution was withdrawn from the dissolution apparatus at specific time intervals. Samples 
were replaced with fresh dissolution medium. The samples were diluted to a suitable 
concentration with 0.1N HCl. The absorbance of these solutions was measured at 212nm 
using a UV Spectrophotometer.  
 
   For FPRT
24, 28
 
 The release of Captopril floating pulsatile tablet was determined using USP Type 
II (Paddle type) apparatus. The dissolution test was performed using 900ml of 0.1N HCl 
(pH 1.2), at 37°C ± 0.5°C. The paddle was rotated at the speed of 50 rpm. A sample 
(10ml) of the solution was withdrawn from the dissolution apparatus at specific time 
intervals for 24 hrs. Samples were replaced with fresh dissolution medium. The samples 
were diluted to a suitable concentration with 0.1N HCl. The absorbance of these solutions 
was measured at 212nm using a UV Spectrophotometer.  
 
II. IN-VITRO BUOYANCY DETERMINATION
22, 24 
 Floating behavior of the tablet was determined using USP dissolution apparatus-II 
(Paddle type) in 900 ml of 0.1 N HCl which is maintained at 37°C ± 0.5°C, rotated at 50 
rpm. The floating lag time (the period between placing FPRT in the medium and 
buoyancy) and floating duration were observed. The matrix integrity of the tablets during 
the study was also visually monitored. 
 
Lag time
24
  
 Lag time was considered as the time when the tablet burst and core tablet is out of 
press coating. This is considered as predetermined off-release period. 
 
MATERIALS AND METHODS 
 
Department of Pharmaceutics, Madras Medical College Page 76 
 
Swelling Index Determination
24, 25 
 Tablets were weighed individually (W1) and placed separately in glass beaker 
containing 200 ml of 0.1N HCl and incubated at 37°C ± 0.5°C. At regular 1–hour time 
intervals until 10hrs, the tablets were removed from the beaker, and the excess surface 
liquid was removed carefully using the tissue paper. The swollen tablets were then 
reweighed (W2) and swelling index (SI) was calculated using the following formula 
    SI = W2 – W1 x 100 
     W1 
 Where, W2 is the wet weight and W1 is the dry weight 
 
IN-VITRO RELEASE KINETICS
87 
Various models were tested for explaining the kinetics of drug release. To analyze 
the mechanism of the drug release rate kinetics of the dosage form, the obtained data 
were plotted in various kinetic models (Zero-order, First order, Higuchi, Hixson-Crowell 
release model and Korsmeyer-Peppas release model). 
1. Zero order equation 
The zero order release can be obtained by plotting cumulative % percentage drug 
release versus time. It is ideal for the formulation to have release profile of zero order to 
achieve pharmacological prolonged action. 
C=K0t 
Where, K0 = Zero order constant 
 t = Time in hours 
2. First order equation 
The graph was plotted as log % cumulative drug remaining Vs time in hours. 
     Log C= log C0 - Kt/2.303 
Where, C0 = Initial concentration of drug 
 K = First order 
   t = Time in hours 
3. Higuchi kinetics 
The graph was plotted with % cumulative drug released vs. square root of time 
Q = Kt
½
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Where, K= constant reflecting design variable system (differential rate 
constant) 
 t = Time in hours 
4. Hixon and Crowell erosion equation 
To evaluate the drug release with changes in the surface area and the diameter of 
particles, the data were plotted using the Hixon and Crowell rate equation. The graph was 
plotted by cube root of % drug remaining vs. time in hours. 
Q0
1/3
 – Qt
1/3
 = KHCXt 
Where, Qt = amount of drug released in time t. 
 Q0 = Initial Amount of drug 
KHC= Rate constant for Hixon Crowell equation 
5. Korsmeyer-Peppas equation 
To evaluate the mechanism of drug release, it was further plotted in Peppas 
equation as log cumulative % of drug released Vs.log time. 
Mt/Mα = Kt
n
 
Where, Mt/Mα = Fraction of drug released at time t 
 t = Release time 
 K=Kinetics constant (Incorporating structural and geometric 
characteristics of  the formulation) 
 n = Diffusional exponent indicative of the mechanism of drug release. 
 
Table 9: Diffusion exponent and solute release mechanism for cylindrical shape 
Diffusion exponent (n) Overall solute diffusion mechanism 
0.45 Fickian diffusion 
0.45 <  n  <  0.89 Anomalous (non- Fickian) diffusion 
0.89 Case II transport 
n > 0.89 Super case II transport 
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STABILITY STUDIES
24, 25 
 A short – term stability study on optimized FPRT was carried out by storing the 
tablets at 40°C (± 2°C) and 75% RH over a period of 90 days according to ICH 
guidelines. At the end of 90 days time interval, the tablets were examined for physical 
characteristics, drug content, in-vitro drug release (lag time), floating lag time, and 
floating duration. 
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The present investigation was to formulate floating pulsatile release tablet for the 
treatment of morning surge of hypertension 
9.1. PREFORMULATION STUDIES 
9.1.1. DRUG – EXCIPIENT COMPATIBILITY STUDY 
The drug-excipient compatibility study was conducted to reveal the excipient 
compatibility with the drug. 
9.1.1.1. PHYSICAL COMPATIBILITY 
Table 10: Physical compatibility study of Drug and Excipients 
S. No. Drug + Excipient 
Description and Condition 
Initial  
Room temperature  and 
40°C / 75% RH in days 
10
th
 20
th
 30
th
 
1 Captopril 
A white to off-white, 
crystalline powder 
NC NC NC 
2 SSG White / off white powder NC NC NC 
3 CCS Grayish-white powder NC NC NC 
4 CP Creamy white powder NC NC NC 
5 Xanthan gum 
Creamy white free flowing fine 
powder 
NC NC NC 
6 HPMC E15 White or Creamy white Powder NC NC NC 
7 HPMC K4M 
White or Creamy white 
Crystalline Powder 
NC NC NC 
8 HPMC K15M 
White or Creamy white 
Crystalline Powder 
NC NC NC 
9 Sodium bicarbonate White, Crystalline Powder NC NC NC 
10 Lactose Off white crystalline powder NC NC NC 
11 MCC White, Crystalline Powder NC NC NC 
12 Magnesium stearate 
White or Off white crystalline 
Powder 
NC NC NC 
13 Talc 
White or Off white crystalline 
Powder 
NC NC NC 
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14 Erythrosine Cherry Pink Colour Powder NC NC NC 
15 Captopril + SSG White / off white powder NC NC NC 
16 Captopril + CCS Grayish-white powder NC NC NC 
17 Captopril + CP Creamy white powder NC NC NC 
18 
Captopril + 
Xanthan gum 
Creamy white free flowing fine 
powder 
NC NC NC 
19 
Captopril +  
HPMC E15 
White or Creamy white Powder NC NC NC 
20 
Captopril +  
HPMC K4M 
White or Creamy white 
Crystalline Powder 
NC NC NC 
21 
Captopril +  
HPMC K15M 
White or Creamy white 
Crystalline Powder 
NC NC NC 
22 
Captopril + Sodium 
bicarbonate 
White, Crystalline Powder NC NC NC 
23 Captopril + Lactose Off white crystalline powder NC NC NC 
24 Captopril + MCC White, Crystalline Powder NC NC NC 
25 
Captopril + 
Magnesium stearate 
White or Off white crystalline 
Powder 
NC NC NC 
26 Captopril + Talc 
White or Off white crystalline 
Powder 
NC NC NC 
27 
Captopril + 
Erythrosine 
Cherry Pinkish Colour Powder NC NC NC 
NC –No change  
The Physical compatibility study was performed visually. The study showed that 
the drug and excipients were physically compatible with each other as there was no 
Physical interaction. The excipients which were compatible with the drugs were selected 
for formulation. 
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9.1.1.2. CHEMICAL COMPATIBILITY STUDY 
81
   
The possible interaction between the drug and the excipients used in the 
formulation was studied by FTIR spectroscopy. The results are given in the below 
 
FTIR SPECTROSCOPY OF DRUG 
 
Fig. 12: FTIR of Captopril 
 
Table 11: IR Spectral interpretation of Captopril 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
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FTIR SPECTROSCOPY OF CAPTOPRIL AND EXCIPIENTS 
 
Fig. 13: FTIR of Captopril with croscarmellose sodium (CCS)  
 
Table 12: IR Spectral interpretation of Captopril with croscarmellose sodium 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
 
The peaks observed in the FTIR spectrum showed no shift and no disappearance 
of characteristic peaks of drugs. This suggests that there was no interaction between the 
drug and Croscarmellose sodium. 
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Fig. 14: FTIR of Captopril with crospovidone (CP)  
 
Table 13: IR Spectral interpretation of Captopril with crospovidone 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
 
The peaks observed in the FTIR spectrum showed no shift and no disappearance 
of characteristic peaks of drugs. This suggests that there was no interaction between the 
drug and Crospovidone. 
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Fig. 15: FTIR of Captopril with sodium starch glycolate (SSG)  
 
Table 14: IR Spectral interpretation of Captopril with sodium starch glycolate 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
 
 The peaks observed in the FTIR spectrum showed no shift and no disappearance 
of characteristic peaks of drugs. This suggests that there was no interaction between the 
drug and Sodium Starch Glycolate. 
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Fig. 16: FTIR of Captopril with HPMC E15 
 
Table 15: IR Spectral interpretation of Captopril with HPMC E15 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
 
The peaks observed in the FTIR spectrum showed no shift and no disappearance 
of characteristic peaks of drugs. This suggests that there was no interaction between the 
drug and HPMC E15. 
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Fig. 17: FTIR of Captopril with HPMC K15M 
 
Table 16: IR Spectral interpretation of Captopril with HPMC K15M 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
 
 The peaks observed in the FTIR spectrum showed no shift and no 
disappearance of characteristic peaks of drugs. This suggests that there was no interaction 
between the drug and HPMC K15M. 
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Fig. 18: FTIR of Captopril with HPMC K4M 
 
Table 17: IR Spectral interpretation of Captopril with HPMC K4M 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
 
 The peaks observed in the FTIR spectrum showed no shift and no 
disappearance of characteristic peaks of drugs. This suggests that there was no interaction 
between the drug and HPMC K4M. 
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Fig. 19: FTIR of Captopril with Xanthan gum 
 
Table 18: IR Spectral interpretation of Captopril with Xanthan gum 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2985 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
  
 The peaks observed in the FTIR spectrum showed no shift and no 
disappearance of characteristic peaks of drugs. This suggests that there was no interaction 
between the drug and Xanthan gum. 
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Fig. 20: FTIR of Captopril powder blend 
 
Table 19: IR Spectral interpretation of Captopril powder blend 
Wave number (cm
-1
) Type of Vibration 
1725 C=O 
2975 C-H (aliphatic) 
2580 -OH (carboxylic acid) 
 
  
The peaks observed in the FTIR spectrum showed no shift and no disappearance 
of characteristic peaks of drugs. This suggests that there was no interaction between the 
drug and excipients (Powder blend). 
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9.2. CALIBRATION CURVE OF CAPTOPRIL 
Table 20: Data for calibration curve of Captopril in 0.1N Hydrochloric acid (pH 1.2) 
Concentration 
(µg/ml) 
Absorbance* 
0 0 
2 0.057 ± 0.0073 
4 0.109 ± 0.0055 
6 0.164 ± 0.0095 
8 0.222 ± 0.0082 
10 0.284 ± 0.0065 
*Mean ± SD (n=3) 
 
 
Fig. 21: Calibration curve of Captopril 
 
It was found that the solutions of Captopril in 0.1N Hydrochloric acid (pH 1.2) 
showed linearity (R
2
 = 0.9996) in absorbance at concentrations of 2 to 10 µg/ml and obey 
Beer Lambert’s Law.    
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9.3. RAPID RELEASE FORMULATION OF CAPTOPRIL 
9.3.1. PRECOMPRESSION STUDY 
The drug and the formulated blends are evaluated for precompression parameters. 
The results are given in the table 21. 
Table 21: Precompression study of drug and formulated blends 
Drug 
Formulation 
Bulk 
density* 
(g/cm
3
) 
Tapped 
density* 
(g/cm
3
) 
Compressibility 
index*  
(%) 
Hausner’s 
ratio* 
Angle of 
repose*  
Captopril 
0.5773 ± 
0.015 
0.6824 ± 
0.022 
15.35 ± 0.57 
1.18 ± 
0.036 
31°31ʹ  ± 
1.61 
F1 
0.5026 ± 
0.008 
0.6669 ± 
0.021 
18.55 ± 0.48 
1.25 ± 
0.042 
42°02ʹ  ± 
0.588 
F2 
 0.4942 ± 
0.118 
0.6385 ± 
0.034 
19.44± 0.76 
1.23 ± 
0.047 
45°22ʹ  ± 
0.205   
F3 
0.4868     
±0.011 
0.6247± 
0.018 
20.01± 0.15 
1.22 ± 
0.038 
45°50ʹ  ± 
0.335 
F4 
0.4791± 
0.0001  
0.5630± 
0.0001 
14.92± 0.001 
1.17± 
0.0002 
44°19ʹ  ± 
0.205 
F5 
0.4681 ± 
0.010 
0.5806± 
0.016 
19.36± 0.443 
1.23± 
0.0065 
43°25ʹ  ± 
0.048 
F6 
0.4228 ± 
0.0089 
0.5322 
± 0.002 
20.56± 0.682 1.25± 0.023 
43°40ʹ  ± 
0.420 
F7 
0.4710 ± 
0.010 
0.5521 ± 
0.014 
14.70± 0.30 1.16± 0.004 
43°45ʹ  ± 
0.35 
F8 
0.479 ± 
0.0001 
0.598 ± 
0.001 
19.89± 0.0002 
1.24± 
0.0002 
42°41ʹ  ± 
0.505 
F9 
0.4825 ± 
0.001  
0.6301 ± 
0.0001 
19.99± 0.0002 
1.24± 
0.0002 
43°56ʹ  ± 
0.590 
*Mean ±S.D (n=3) 
 
The bulk density, tapped density, Carr’s index, Hausner’s ratio, Angle of repose 
of drug were found to be 0.5773, 0.6824, 15.35, 1.18, 31°31ʹ  respectively.  
The bulk density of Captopril blends ranged from 0.4228 to 0.5026 g/cm
3
 and 
tapped density ranged from 0.5322 to 0.6669 g/cm
3
. The compressibility index of the 
Captopril powder blend ranged from 14.70 to 20.56% and Hausner’s ratio ranged from 
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1.16 – 1.25 which showed fair-good flow. The angle of repose of Captopril powder blend 
ranged from 42°02ʹ  to 45°50ʹ  which showed passable flow property. 
 
Table 22: Precompression study of formulated blends with lubricant 
Drug 
Formulation 
Bulk 
density* 
(g/cm
3
) 
Tapped 
density* 
(g/cm
3
) 
Compressibility 
index*  
(%) 
Hausner’s 
ratio* 
Angle of 
repose*  
F1 
0.5070 ± 
0.012 
0.6487 ± 
0.020 
17.82 ± 0.546 
1.23 ± 
0.0094 
35°41ʹ  ± 
0.1518 
F2 
 0.5472 ± 
0.014 
0.7118 ± 
0.024 
18.08 ± 0.612 
1.21 ± 
0.0091 
40°43ʹ  ± 
0.025   
F3 
0.5349 ± 
0.024 
0.6272 ± 
0.018 
14.74  ± 2.13 1.17± 0.029 
37°29ʹ  ± 
0.241 
F4 
0.5063 ± 
0.0001  
0.5894± 
0.016 
14.15± 2.57 
1.16 ± 
0.036 
40°21ʹ  ± 
0.135 
F5 
0.4899 ± 
0.0119 
0.5559 ± 
0.014 
11.83 ± 2.235 
1.13 ± 
0.028 
39°26ʹ  ± 
0.390 
F6 
0.4585 ± 
0.0001 
0.5256 ± 
0.013 
12.70 ± 2.24 
1.14 ± 
0.042 
38°56ʹ  ± 
0.331 
F7 
0.5145 ± 
0.013 
0.5898 ± 
0.035 
12.57 ± 2.89 
1.14 ± 
0.028 
39°17ʹ  ± 
0.145 
F8 
0.524 ±  
0.013 
0.627 ±  
0.018 
16.14 ± 0.419 
1.19 ± 
0.009 
33°58ʹ  ± 
0.385 
F9 
0.548 ±  
0.014  
0.660 ±  
0.018 
16.99± 0.457 
1.20 ± 
0.004 
37°23ʹ  ± 
0.518 
*Mean ±S.D (n=3) 
 
The bulk density of Captopril blends ranged from 0.4585 to 0.548 g/cm
3
 and 
tapped density ranged from 0.5256 to 0.7118 g/cm
3
. The compressibility index of the 
Captopril powder blend ranged from 11.83 to 18.08% and Hausner’s ratio ranged from 
1.13 – 1.23 which showed fair-good flow. The angle of repose of Captopril powder blend 
ranged from 33°58ʹ  to 40°43ʹ  which showed fair-good flow property. 
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9.3.2. POST COMPRESSION STUDY 
UNIFORMITY OF WEIGHT 
The uniformity of weight of the formulated tablets is given in table 23 
Table 23: Uniformity of weight of the RRCTs 
Formulation 
Uniformity weight* 
(mg) 
F1 99.54  
F2 99.36  
F3 99.88  
F4 99.50  
F5 100.14  
F6 100.48  
F7 100.30  
F8 100.61  
F9 100.72  
  *Mean ±S.D (n=20)  
The tablets comply with the test for uniformity of weight 
 
TABLET THICKNESS AND DIAMETER 
The thickness and diameter of the formulated tablets is given in table 24 
 
Table 24: Thickness and diameter of the RRCTs 
Formulation 
Thickness* 
(mm) 
Diameter* 
(mm) 
F1 2 ± 0.0 6 ±  0.0 
F2 2 ± 0.0 6 ±  0.0 
F3 2 ± 0.0 6 ±  0.0 
F4 2 ± 0.0 6 ±  0.0 
F5 2 ± 0.0 6 ±  0.0 
F6 2 ± 0.0 6 ±  0.0 
F7 2 ± 0.0 6 ±  0.0 
F8 2 ± 0.0 6 ±  0.0 
F9 2 ± 0.0 6 ±  0.0 
*Mean ±S.D (n=5)  
The tablets have uniform thickness and diameter. 
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 HARDNESS 
Table 25: Hardness of the RRCTs 
Formulation 
Hardness* 
(kg/cm
2
) 
F1 2.7 ± 0.244 
F2 2.3 ± 0.244 
F3 2.5 ± 0.218 
F4 2.8 ± 0.241 
F5 2.5 ± 0.244 
F6 2.3 ± 0.210 
F7 2.8 ± 0.241 
F8 2.7 ± 0.244 
F9 2.6 ± 0.216 
*Mean ±S.D (n=5) 
The hardness of the tablets was found to be between 2.3 kg/cm
2
 and 2.8 kg/cm
2
.  
All the formulated tablets showed sufficient mechanical strength to resist stress during 
the transportation
26
 
 
FRIABILITY 
Table 26: Friability of the RRCTs 
Formulation 
Friability* 
(%) 
F1 0.476 ± 0.284 
F2 0.538 ± 0.365 
F3 0.348 ± 0.214 
F4 0.561 ± 0.341 
F5 0.648 ± 0.244 
F6 0.636 ± 0.176 
F7 0.590 ± 0.198 
F8 0.650 ± 0.289 
F9 0.562 ± 0.302 
*Mean ±S.D (n=3)  
The percentage friability of the tablets ranged from 0.348 % to 0.648 %. The 
percentage friability of all the formulation was within Pharmacopeial limits
84
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DRUG CONTENT  
The drug content of the Rapid release core tablets is given in the table 27  
Table 27: Drug content of the RRCTs 
Formulation 
Drug content* 
(%) 
F1 93.15 ± 0.235 
F2 93.68 ± 0.342 
F3 96.68 ± 0.215 
F4 94.71 ± 0.359 
F5 98.61 ± 0.256 
F6 100.54 ± 0.328 
F7 95.14 ± 0.268 
F8 97.60 ± 0.318 
F9 95.56 ± 0.275 
*Mean ± SD (n=3) 
 
 
Fig. 22: Drug content of the formulated rapid release tablets 
  
The percentage drug content of Captopril in all the formulations ranged from 
93.15 %w/w to 100.54 %w/w. All the formulations comply with the official standards
79
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DISINEGRATION TIME 
Table 28: Disintegration time of RRCTs 
Formulation 
Disintegration time* 
(seconds) 
F1 38 ± 0.015 
F2 30 ± 0.023 
F3 21 ± 0.012 
F4 37 ± 0.030 
F5 29 ± 0.018 
F6 23 ± 0.025 
F7 53 ± 0.021 
F8 48 ± 0.017 
F9 43 ± 0.026 
*Mean ±S.D (n=3) 
 
            
Fig. 23: Disintegration time of the formulated rapid release tablets 
 The disintegration time of the Captopril tablets ranged from 21 seconds to 53 
seconds. The disintegration time of captopril core tablet (F3) containing croscarmellose 
sodium (2%) as a super disintegrant was found to be the optimum core tablet for final 
tablet. All the formulations comply with the official standards.
84, 85
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IN-VITRO DISSOLUTION STUDY 
The invitro dissolution of RRCTs of Captopril is given in the Table 29 
 
Table 29: in-vitro dissolution of rapid release formulation of Captopril 
Time 
(min) 
Percentage Drug release* 
F1 F2 F3 F4 F5 F6 F7 F8 F9 
1 
42.21 
± 3.53 
48.69 
± 2.26 
46.86 
± 2.49 
29.62 
± 2.26 
32.08 
± 2.39 
40.68 ± 
1.13 
- - - 
2 
61.65 
± 2.24 
84.98 
± 3.38 
88.55 
± 2.14 
38.69 
± 2.85 
44.68 
± 2.35 
60.89 ± 
2.26 
- - - 
3 
72.07 
± 1.33 
87.30 
± 3.40 
98.31 
± 2.14 
57.09 
± 1.68 
60.63 
± 1.20 
88.55 ± 
2.14 
- - - 
4 
75.22 
± 2.59 
95.05 
± 2.21 
104.5 
± 1.22 
68.76 
± 1.73 
76.31 
± 2.43 
92.94 ±  
2.80 
- - - 
5 
78.37 
± 1.32 
98.58 
± 2.23 
 
72.08 
± 1.76 
86.01 
± 1.20 
96.05 ± 
3.74 
43.86 
± 1.18 
45.65 
± 2.35 
58.56 
± 1.63 
6 
87.97 
± 2.24 
106.8 
± 1.56 
 
86.73 
± 1.11 
95.32 
± 1.13 
103.7 ± 
3.14 
- - - 
7 
95.77 
± 3.45 
  
91.08 
± 1.26 
102.8 
± 0.71 
 - - - 
8 
100.87 
± 1.29 
  
96.48 
± 2.36 
  - - - 
9    
103.8 
± 1.78 
  - - - 
10       
51.78 
± 1.08 
54.83 
± 2.06 
66.55 
± 1.86 
15       
53.81 
± 1.63 
67.01 
± 2.34 
74.66 
± 1.98 
20       
58.79 
± 1.18 
70.57 
± 1.76 
87.28 
± 2.13 
25       
71.35 
± 2.36 
77.12 
± 1.58 
97.09 
± 1.53 
30       
75.06 
± 2.32 
83.69 
± 2.26 
103.98 
± 1.18 
35       - 
91.74 
± 2.24 
 
40       
80.21 
± 2.38 
99.97 
± 1.18 
 
50       
101.26 
± 1.18 
  
*Mean ±S.D (n=3) 
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Fig. 24: in vitro drug release of formulated captopril rapid release tablets 
 
    
Fig. 25: in vitro drug release of formulated captopril rapid release tablets 
 
 From the in-vitro release study, it was found that Formulation F3 containing 2% 
CCS showed rapid release of 98.31±2.14 at the end of 3 minutes compared to other 
formulations. So, F3 was optimized for final formulation. 
 Formulation F7 (2% SSG) showed slow release compared to other formulations. 
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9.4. FLOATING PULSATILE RELEASE TABLET OF CAPTOPRIL 
9.4.1. PRECOMPRESSION STUDY     
The formulated coating material blends are evaluated for Pre-compression 
parameters. The results are given in the table 30. 
 
Table 30: Precompression study of formulated blends of coating materials 
Drug 
Formulation 
Bulk 
density* 
(g/cm
3
) 
Tapped 
density* 
(g/cm
3
) 
Compressibility 
index*  
(%) 
Hausner’s 
ratio* 
Angle of 
repose* 
FP1 
0.6114 ± 
0.0089 
0.722 ± 
0.012 
15.31 ± 0.226 
1.18 ± 
0.0032 
38°50ʹ  ± 
0.345 
FP2 
 0.6509 ± 
0.010 
0.7581 ± 
0.013 
14.11 ± 1.42 
1.16 ± 
0.0019 
29°24ʹ  ± 
0.190   
FP3 
0.6732 ± 
0.010 
0.7782 ± 
0.014 
13.48 ± 0.216 
1.15 ± 
0.0032 
31°21ʹ  ± 
0.995 
FP4 
0.6522 ± 
0.010  
0.802 ± 
0.015 
18.67 ± 1.43 
1.22 ± 
0.021 
35°39ʹ  ± 
0.540 
FP5 
0.6221 ± 
0.017 
0.740 ± 
0.001 
15.92 ± 2.42 
1.18 ± 
0.032 
33°46ʹ  ± 
0.425 
FP6 
0.6115 ± 
0.008 
0.7147 ± 
0.012 
14.42 ± 1.37 
1.16 ± 
0.016 
32°08ʹ  ± 
0.880 
FP7 
0.6139 ± 
0.017 
0.752 ± 
0.025 
18.37 ± 0.51 
1.22 ± 
0.0094 
31°37ʹ  ± 
0.495 
FP8 
0.6657 ±  
0.024 
0.820 ±  
0.001 
18.82 ± 2.30 
1.23 ± 
0.047 
36°54ʹ  ± 
0.445 
*Mean ±S.D (n=3) 
 
The bulk density of coating material blends ranged from 0.6114 to 0.6732 g/cm
3
 
and tapped density ranged from 0.7147 to 0.820 g/cm
3
. The compressibility index of the 
coating material powder blend ranged from 13.48 to 18.80% and Hausner’s ratio ranged 
from 1.15 – 1.23. The angle of repose of coating material powder blend ranged from 
29°24ʹ  to 38°50ʹ . The formulated coating material powder blend showed good flow 
property. 
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9.4.2. POST COMPRESSION STUDY 
UNIFORMITY OF WEIGHT 
The uniformity of weight of the formulated tablets is given in table 31. 
Table 31: Uniformity of weight of the FPRTs 
Formulation 
Uniformity weight* 
(mg) 
FP1 504.7  
FP2 498.11  
FP3 498.5  
FP4 497.22  
FP5 496.34  
FP6 499.99  
FP7 499.54  
FP8 501.22  
  *Mean ±S.D (n=20)  
The tablets comply with the test for uniformity of weight 
 
THICKNESS AND DIAMETER  
The thickness and diameter of the formulated tablets is given in table 32. 
 
Table 32: Thickness and diameter of the FPRTs 
Formulation 
Thickness* 
(mm) 
Diameter* 
(mm) 
FP1 4 ± 0.0 10 ±  0.0 
FP2 4 ± 0.0 10 ±  0.0 
FP3 4 ± 0.0 10 ±  0.0 
FP4 4 ± 0.0 10 ±  0.0 
FP5 4 ± 0.0 10 ±  0.0 
FP6 4 ± 0.0 10 ±  0.0 
FP7 4 ± 0.0 10 ±  0.0 
FP8 4 ± 0.0 10 ±  0.0 
*Mean ±S.D (n=5)  
The tablets have uniform thickness and diameter. 
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HARDNESS 
Table 33: Hardness of the FPRTs 
Formulation 
Hardness* 
(kg/cm
2
) 
FP1 4.9 ± 0.374 
FP2 5.1 ± 0.374 
FP3 4.8 ± 0.244 
FP4 4.8 ± 0.244 
FP5 4.7 ± 0.244 
FP6 4.9 ± 0.210 
FP7 4.6 ± 0.244 
FP8 4.8 ± 0.210 
*Mean ±S.D (n=5) 
The hardness of the tablets was found to be between 4.7 kg/cm
2
 and 5.1 kg/cm
2
.  
All the formulated tablets showed sufficient mechanical strength to resist stress during 
the transportation
84
 
 
FRIABILITY  
Table 34: Friability of the FPRTs 
Formulation 
Friability* 
(%) 
FP1 0.741 ± 0.0351 
FP2 0.649 ± 0.0265 
FP3 0.572 ± 0.0376 
FP4 0.560 ± 0.0278 
FP5 0.736 ± 0.0198 
FP6 0.589 ± 0.0267 
FP7 0.638 ± 0.0356 
FP8 0.654 ± 0.0263 
*Mean ±S.D (n=3)  
The percentage friability of the tablets ranged from 0.560 % to 0.741 %. The 
percentage friability of all the formulation was within Pharmacopeial limits
84
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DRUG CONTENT  
The drug content of the Captopril FPRT is given in the table 35 
Table 35: Drug content of the formulated tablets 
Formulation 
Drug content* 
(%) 
FP1 96.56 ± 0.178 
FP2 93.71 ± 0.245 
FP3 93.00 ± 0.269 
FP4 92.01 ± 0.312 
FP5 95.99 ± 0.287 
FP6 93.71 ± 0.189 
FP7 96.13 ± 0.223 
FP8 95.29 ± 0.256 
*Mean ± SD (n=3) 
 
 
Fig. 26: Drug content of the formulated floating pulsatile release tablets 
 
 The percentage drug content of Captopril in all the formulations ranged 
from 93.00% w/w to 96.56 % w/w. All the formulations comply with the official 
standards
79
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INVITRO FLOATING STUDIES 
     The invitro floating characteristics of Captopril floating FPRT is given in the table 36. 
Table 36: in-vitro floating characteristics of Captopril FPRT 
Formulation 
Floating lag time* 
(minutes) 
Floating duration* 
(hours) 
FP1 15 min 30 sec > 12hrs 
FP2 2 min 50 sec > 24hrs 
FP3 2 min 05 sec > 24hrs 
FP4 14 min 08 sec > 24hrs 
FP5 8 min 17 sec > 12hrs 
FP6 9 min 15 sec > 12hrs 
FP7 8 min 32 sec > 12hrs 
FP8 7 min 30 sec > 12hrs 
*MEAN±S.D (n=3) 
 
         
    Fig. 27: Floating lag time of the formulated floating pulsatile release tablets 
  
The floating duration was ranged from 12 - >24 hours and the floating lag time 
ranged from 2 – 15 minutes.25 The matrix integrity of the prepared floating tablets is good 
during the floating study. The formulation FP3 exhibits optimum floating behavior when 
compared with all the other formulations.
22
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SWELLING STUDIES 
 Swelling study was carried out for floating pulsatile release tablets of captopril. 
The % swelling index of the captopril floating pulsatile tablets were given in the Table 37 
and Fig. 26 
 
Table 37: Swelling index (%) of Captopril FPRTs 
Time 
(hrs) 
% Swelling index 
FP1 FP2 FP3 FP4 FP5 FP6 FP7 FP8 
1 10.75 102.36 88.36 93.45 12.52 15.13 50.32 69.12 
2 24.79 160.88 150.22 140.34 39.09 48.05 96.89 101.18 
3 45.65 198.78 180.98 169.24 58.93 69.32 131.66 142.50 
4 36.67 220.99 205.67 199.90 69.56 76.90 152.65 169.54 
5 20.19 249.89 238.78 239.72 52.67 56.12 121.54 135.87 
6 11.63 275.56 259.54 269.82 36.71 43.28 106.75 112.98 
7 0.56 298.32 289.31 290.94 19.01 31.13 82.15 89.76 
8  330.34 305.14 315.06 8.05 20.46 59.15 68.43 
9  368.21 349.91 359.35 1.23 12.07 42.56 51.98 
10  354.43 332.13 342.86  3.08 31.57 39.13 
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Fig. 28: Swelling index of Captopril FPRTs 
  
 
 The swelling behavior of FPRT containing HPMC E15, HPMC K15M, HPMC 
K4M, Xanthan gum individually and in combination was compared. The obtained results 
showed that the swelling front erodes faster for HPMC E15 (150 mg) and the swelling 
front erosion was comparably slower in FPRTs with increased concentration of       
HPMC E15 and HPMC E15 in combination.
25
 
 FPRT containing HPMC K15M showed the highest swelling index as compared 
to HPMC K4M, HPMC E15, and Xanthan gum. HPMC K4M, Xanthan gum and     
HPMC K15M showed a constant increase in the swelling index up to 9 hrs, after this 
there was a decrease due to the start of tablet erosion.
22
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IN-VITRO DISSOLUTION STUDY 
The invitro dissolution of floating pulsatile formulations of Captopril is given in the 
Table 38 
 
Table 38: in-vitro dissolution of floating pulsatile formulations of Captopril 
Time 
(hr) 
Percentage Drug release 
FP1 FP2 FP3 FP4 FP5 FP6 FP7 FP8 
1 3.15 3.25 3.27 3.31 5.83 4.61 3.16 4.68 
2 5.83 8.74 8.81 3.34 13.90 8.76 5.86 4.73 
3 9.87 10.20 13.03 7.55 18.05 15.83 5.93 6.17 
3.5 98.74 - - - - - - - 
3.75 103.81 - - - - - - - 
4 - 15.78 22.08 10.41 100.90 71.84 9.99 13.17 
4.25 - - - - - 101.31 - - 
5 - 17.32 29.93 13.31 - - 94.04 17.47 
5.5 -  - - - - 103.07 - 
6 - 20.97 48.14 17.62 - - - 20.38 
7 - 42.31 56.92 20.59 - - - 89.17 
7.5 - - - - - - - 101.23 
8 - 55.07 67.16 38.89 - - - - 
9 - 65.24 80.26 44.68 - - - - 
10 - 72.01 90.76 54.48 - - - - 
11 - 77.56 99.98 68.78 - - - - 
24 - 89.98 108.66 88.18 - - - - 
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    Fig. 29: in vitro drug release of formulated FPRT 
 
 
 
Fig. 30: in vitro drug release of formulated FPRT 
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From the invitro release study, it was found that Formulation containing       
HPMC E15 individually and in combination showed a burst release after a lag time, 
whereas formulations containing HPMC K15M, HPMC K4M and Xanthan gum showed 
controlled release. 
 Formulation FP8 showed a satisfactory drug release of 101.23% with a lag time of 
6hrs. So, the formulation was optimized for morning surge of hypertension 
 
9.5. INVITRO RELEASE KINETICS 
The values obtained from invitro dissolution of Captopril floating pulsatile release 
tablet were fitted in various kinetic models. The results are given in table 39 and Figure 
30, 31, 32, 33 and 34. 
 
Table 39: in vitro release kinetics of optimized FPRT 
Time 
(Hours) 
Log 
time 
(Hours) 
Sq. Root 
of time 
(Hours) 
Cum % 
drug 
release 
Cum % 
drug 
remaining 
Log 
cum % 
drug 
release 
Log cum 
% drug 
remaining 
Cube root 
of cum % 
drug 
remaining 
0 ∞ 0 0 102.25 ∞ 2.009 4.676 
1 0 1 3.29 98.96 0.517 1.995 4.625 
2 0.301 1.414 5.17 97.08 0.713 1.987 4.595 
3 0.477 1.732 6.62 95.63 0.820 1.980 4.572 
4 0.602 2 12.22 90.03 1.087 1.954 4.481 
5 0.698 2.236 16.99 85.26 1.230 1.930 4.401 
6 0.778 2.449 21.33 80.92 1.328 1.908 4.325 
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Fig. 31: Zero order kinetics 
 
 
 
Fig. 32: First order kinetics 
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Fig. 33: Higuchi diffusion kinetics 
 
 
 
Fig. 34: Hixson crowell release kinetics 
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Fig. 35: Korsmeyer Peppas release kinetics 
 
 The optimized FPRT (FP8) follows zero order kinetics up to the lag time, in 
which the regression value was 0.963. 
 The ‘n’ value of Korsmeyer-peppas equation was found to be 1.066. From this it 
was concluded that the drug release follows non-fickian super case II transport. 
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9.6. STABILITY STUDIES 
 The stability studies of the optimized formulations are done at ambient room 
temperature and 40ºC ± 2ºC maintained at RH 75% ± 5% for 45 days. 
  
Table 40: Stability study of Captopril FPRT– Optimized formulation 
Sample 
withdrawal 
period 
Drug content (in % w/w) 
Percentage drug release  
(at the end of 7.5 hours)  
At Ambient 
temperature 
40ºC ± 2ºC 
and 75% ± 
5% RH 
At Ambient 
temperature 
40ºC ± 2ºC 
and 75% ± 
5% RH 
0
th
 day 96.54 96.21 101.13 99.65 
15
th
 day 96.87 95.80 99.91 101.50 
30
th
 day 97.35 96.54 100.67 99.79 
45
th
 day 97.15 96.98 98.70 99.32 
 
 
 
Fig. 36: Stability study of Captopril FPRT – Drug content analysis 
 
There was no significant difference in the physical appearance of the formulation. 
 
95
96
97
98
0 15 30 45
%
 D
R
U
G
 C
O
N
T
E
N
T
 
Sample withdrawal Period (in days) 
STABILITY STUDIES OF CAPTOPRIL FPRT- 
DRUG CONTENT ANALYSIS 
At Ambient temperature
40ºC ± 2ºC and 75% ± 5%
RH
RESULTS AND DISCUSSION 
 
Department of Pharmaceutics, Madras Medical College Page 113 
 
 
 
Fig. 37: Stability study of Captopril FPRT – Drug release study 
 
 Short term stability studies of the optimized FPRT (FP8) indicated that 
there were no significant difference in the results of drug content analysis and the in-vitro 
drug release at the end of stability study. This shows that the formulations remained 
stable during the process of storage.  
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The present work involves the design, development and in-vitro evaluation of 
Captopril floating pulsatile release tablet, in which the core tablets are rapid release 
formulation which is coated with hydrophilic polymers such as HPMC E15,            
HPMC K15M, HPMC K4M, Xanthan gum individually and in combination. FPRT was 
designed for the treatment of morning surge of Hypertension. 
The drug excipient interaction was investigated with FTIR spectroscopy. The 
study indicated that there was no interaction between the drug and the excipients used in 
the formulations.  
The rapid release core tablets of captopril were formulated with various 
concentrations of SSG (2%, 3% and 4%), CCS (1%, 1.5% and 2%) and Crospovidone    
(2 %, 3.5% and 5%) by direct compression. 
The formulated RRCT blends were evaluated for pre-compression parameters 
which showed good flow property.  
The formulated tablets were found to be within the limits with respect to Weight 
uniformity, Hardness, Thickness, Diameter and Friability. 
The Drug content of the formulated Tablets was found to be within the 
Pharmacopoeial limit. 
The Disintegration time of Captopril rapid release Core Tablet (Formulation F3) 
containing 2% croscarmellose sodium disintegrated quickly (D.T = 21 seconds). 
The in-vitro dissolution studies of the formulated Captopril Core tablets were 
performed using USP type-II dissolution apparatus. From the formulated batches, the 
formulation F3 released the drug very quickly (within 4 minutes) when compared to other 
formulations. 
Based on the Disintegration and in-vitro release studies of captopril rapid release 
core tablets, formulation F3 was optimized and selected for Press coating. 
The outer coat contains hydrophilic polymers (swellable and erodible) such as 
HPMC E15, HPMC K15M, HPMC K4M, Xanthan gum. For the formulated coating 
material blends, micromeritic properties were evaluated which showed good flow. So, the 
Compression coating of optimized Captopril core tablets was done by direct compression 
technique. 
 Totally 8 batches of Captopril Floating pulsatile release tablets (FPRT) were 
prepared using HPMC E15, HPMC K15M, HPMC K4M, Xanthan gum. 
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The formulated Captopril FPRTs were found to be within limits with respect to 
Weight uniformity, Hardness, Thickness, Diameter and Friability. 
The drug content of the Captopril FPRTs were estimated and found to be within 
Pharmacopoeial limits. 
A direct correlation between swelling and lag time was observed and found that 
the formulations having maximum swelling indices showed higher lag time.    
The in-vitro dissolution studies of the formulated Captopril FPRTs were 
performed using USP type-II dissolution apparatus. From the formulated batches, the % 
drug release for the formulation FP8 was 101.23% at the end of 7.5hrs with the lag time 
of 6hours.  
Based on the in-vitro release studies of Captopril FPRT, formulation FP8 
(formulation contains 200mg of HPMC E15 and 50mg of HPMC K4M) was optimized. 
The optimized FPRT (FP8) follows Zero order kinetics up to the lag time, in 
which the regression value was 0.963. The ‘n’ value of Korsmeyer-peppas equation was 
found to be 1.066. From this it was concluded that the drug release follows non-fickian 
super case II transport. 
A stability study for the optimized Captopril FPRT was performed by storing the 
tablets at ambient room temperature and at 40ºC ± 2ºC maintained at RH 75% ± 5% for 
45 days. There was no significant differences produced in physical appearance, drug 
content and % drug release, this shows that the formulation remains stable during the 
storage. 
 
FUTURE PLAN:  
 Scale up studies of the optimized formulation 
 in-vivo studies and in vitro-vivo correlation studies 
 Bioequivalence studies with marketed products 
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